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ABSTRACT 
The liver is a key metabolic organ. The liver has adapted to the different 
metabolic needs in men and women, and therefore responds in a sex-specific 
manner to various stimuli. Specific genes have recently been related to the 
development of hepatic insulin resistance (IR) and with our improved 
knowledge of sex differences in fuel metabolism, it may be postulated that 
the liver has a crucial role in sex-dependent development of IR. To improve 
the prevention and treatment of hepatic IR, a better understanding of the 
mechanisms behind sex-differentiated hepatic metabolism is needed. The 
general aim of this thesis was to investigate if there is a relationship between 
sex differences in hepatic fuel metabolism and development of IR.  
 
Sex differences in hepatic fuel metabolism were characterized in healthy 
male and female rats (Paper I). Male rats showed higher ratios of insulin to 
glucagon levels, higher levels of hepatic glycogen, lower degree of hepatic 
AMPK phosphorylation, higher expression of hepatic gluconeogenic genes 
and higher hepatic glucose output, as compared to the females. Effects of 
short-term high-fat feeding on hepatic insulin sensitivity, gene expression, 
lipid metabolism and plasma lipids in healthy male rats were shown to depend 
on the lipid source (Paper II). Safflower oil-enriched diet increased hepatic β-
oxidation, was beneficial in terms of circulating VLDL-TG, but led to 
reduced hepatic insulin sensitivity. Cocoa butter-enriched diet did not affect 
plasma total TG levels, VLDL-TG or hepatic insulin sensitivity. However, 
effects observed on hepatic gene expression indicated that prolonged cocoa 
butter feeding might lead to increased lipid synthesis, and concomitant 
lipotoxicity, inflammation, and IR. The role of hepatic sex differences in 
metabolic pathways in the development of glucose intolerance and IR was 
investigated using Zucker diabetic fatty (ZDF) rats (Paper III). It was shown 
that high-fat feeding in female ZDF rats lead to a more male-like hepatic 
phenotype, including reduced lipogenesis, increased FA oxidation and ROS 
production, while glucose intolerance and IR developed. Sex differences in 
hepatic metabolic control were also observed at the level of hepatic 
metabolites (Paper I and III). Metabolite profiles generated from hepatic 
perfusates from healthy rats using 1NMR spectroscopy verified that male 
livers exported more glucose than females. Liver-derived lactate was also 
higher in males, and there was a trend towards higher levels of glycerol and 
glucogenic amino acids. Testosterone treatment in male ZDF rats reduced 
hepatic fat content but increased blood glucose levels, reduced glucose 
tolerance and increased circulating levels of TG-rich VLDL particles (Paper 
IV). Surprisingly, testosterone reduced STAT3 activity, a key mediator of 
leptin actions in liver and essential for hepatic insulin sensitivity.  
 
Taken together, these findings suggest that the hepatic functions of female rats 
might contribute to a lower risk of developing lipid-induced oxidative stress 
and hepatic IR. Observations of key metabolic transcripts suggest that the 
capacity of females to retain lipogenesis and the secretion of VLDL-TG might 
be related to this. We speculate that this together with higher rates of FA 
oxidation and glucose production in males, might at least partly explain why 
males are more prone to develop insulin resistance, T2D and the metabolic 
syndrome.  
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1 INTRODUCTION 
 
Sex is established by the set of XX or XY chromosomes. This genotype is 
responsible for a sex-specific phenotype including the development of a sex-
specific hormonal system. This sex-specific endocrine system includes the 
central nervous system (CNS), the gonads and several other tissues. The 
manifestation of a sex-specific endocrine system is not only dependent on 
the genotype - also environmental and epigenetic factors play a role.  
Amongst a variety of different sex-different functions, sex differences in 
metabolism have received attention. Studies on sex-different metabolism are 
of interest from different perspectives; in some situations e.g. pregnancy 
there is a need to alter metabolic functions and the incidence of several 
disorders that can be connected to metabolism have a sex-dependent 
distribution. Various aspects can be put on the development of sex 
differences in organisms. In this thesis we put the focus on the existence of 
sex differences manifested after puberty.   
 
In this situation the sex hormones, androgens and estrogens, regulate 
functions of metabolically active tissues such as adipose, liver and skeletal 
muscle [1, 2]. For instance, the regulation of body fat distribution is 
influenced by changes in gonadal sex hormones, including the adipose-
derived hormone leptin, via the hypothalmus [3]. In the liver, metabolism of 
steroid hormones and drugs has been shown to be sexually differentiated, 
mainly due to gonadal hormones causing differences in the growth hormone 
(GH) secretion pattern. Studies in rodents have indicated that sex 
differences in hepatic steroid metabolism may support a pregnant state when 
the liver is exposed to high continuous levels of steroid hormones [4]. Thus, 
sex differences may underlie the development of obesity and other related 
metabolic disorders like insulin resistance [3]. It is an on-going and 
important effort to better understand the functional significance of sex 
differences in metabolism and to put these in relation to disorders that can 
be coupled to metabolism. Sex differences are observed in many common 
disorders, such as type 2 diabetes (T2D) [5] and the metabolic syndrome [6, 
7]. Thus, improved knowledge about the mechanisms contributing to these 
sex differences may have a substantial impact on the prevention, diagnosis 
and treatment of these diseases [8-10].  
 
 
1.1 Sex differences in body composition and metabolism 
 
It is well known that men and women have different body compositions. 
Men tend to have more skeletal muscle mass [11], different types of muscle 
fibers [12, 13] and heavier bones than women. Also, the fat depots differ 
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between the sexes. In general, women tend to have more fat distributed in 
both muscle and adipose tissue. Furthermore, when fat mass is increased 
and stored in excess, men are more likely to develop abdominal obesity with 
visceral fat around the digestive organs, whereas fertile women have a larger 
distribution of subcutaneous fat in the gluteal-femoral region [9, 14-16]. 
However, after menopause when estrogen levels decrease in women, these 
sex differences tend to diminish and a change in fat distribution occurs. A 
majority of postmenopausal women observe an increase in visceral fat [17-
19]. 
 
Differences in body composition are presumably due to sex differences in 
metabolism. Out of the total fat content in a digested meal, men use 56% for 
energy production via fatty acid (FA) oxidation, 7% is stored in the lower 
body (subcutaneously) and 14% is stored in the upper parts of the body 
(visceral). In contrast, women use 41% of the digested fat for oxidation, 22% 
is stored in the lower body and 25% is stored in the upper body [20, 21]. 
 
An upper body/visceral fat distribution in obesity is strongly linked with the 
metabolic complications of obesity hence the development of metabolic 
disease. The delivery of excess FFA to the liver from systemic or visceral 
adipose tissue lipolysis will prevent the normal insulin mediated suppression 
of glucose output by the liver [22] hence, a reduction in hepatic insulin 
sensitivity. 
 
 
1.1.1 Insulin resistance 
 
Insulin resistance (IR) has a strong predictive value with respect to the 
development of T2D and together with decreased insulin production from β-
cells of the pancreas it provides the pathophysiological background for T2D 
[23, 24]. Initially, β-cells compensate for IR by increasing insulin secretion, 
leading to hyperinsulinemia. However, as time goes by, the β-cell function 
becomes altered and fails to compensate for increasing IR and blood glucose 
levels increase and hyperglycemia develops [25]. Depending on the target 
tissue, IR has different definitions. Hepatic IR is defined as an impaired 
ability of insulin to suppress hepatic glucose production through 
gluconeogenesis or to inhibit glucose output from the liver. Peripheral IR is 
defined as inhibition of normal insulin stimulation of whole body glucose 
uptake, e.g. to promote glucose uptake in muscle [26].  
 
IR is a central component in the so-called metabolic syndrome. The 
definition of the syndrome has been extensively discussed, but in 1998 the 
World Health Organisation (WHO) recommended a definition of the 
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metabolic syndrome that includes IR, fasting hyperglycemia, impaired 
glucose tolerance or T2D, hypertension and hyperlipidemia [27]. 
 
IR is reported to be more common in obese men compared to obese 
premenopausal women. Only within the past decades a great deal of effort 
has been dedicated to uncover the relevant physiological differences 
between the sexes that may affect the prevention, diagnosis and treatment of 
disorders such as T2D. In the case of T2D, it is not clear whether the 
disorder is more common in one of the sexes. Recent investigations indicate 
that there is a sex shift within late-onset diabetes. Fertile women seem to be 
more insulin sensitive than men and therefore protected against T2D. 
However, after menopause, women develop IR  to a greater extent and are 
no longer protected against T2D and other metabolic problems [28, 29]. 
Also, T2D affects men and women differently. Reports from population 
studies conclude that diabetic women suffer more from lipid abnormalities 
than diabetic men. Women with diabetes also have an increased risk for 
developing and die from cardiovascular disease [30]. It is evident that sex 
and sex-related differences are important factors in the understanding of 
development of metabolic disease. 
 
Interestingly, a number of studies have shown that the highest risk for 
development of the metabolic syndrome and diabetes occurs in adults who 
are born small and become overweight in early childhood. It is proposed 
that the environment surrounding the developing fetus in uterus may 
permanently influence long-term health and disease in the adult. Intrauterine 
growth restriction (IUGR), due either to maternal, placental, or genetic 
factors, may permanently alter the endocrine–metabolic status of the fetus 
[31]. A temporary IR state can promote survival for a short period of time if 
needed. However, it may facilitate the development of T2D and metabolic 
syndrome in adult life [32, 33]. This occurs especially when the intrauterine 
nutrient restriction is followed by a postnatal obesogenic environment. 
Furthermore, an energy-rich environment during fetal programming may 
also drive the development of excess abdominal fat and T2D in later life, 
demonstrating that both intrauterine nutrient restriction as well as 
intrauterine nutrient excessive supply may predispose for the development 
of adult diabetes.  
 
T2D is known to be a multi-factorial disease and resulting from the 
interaction between specific genes and environmental factors such as diet 
and physical activity. Today, 27 gene variants have been confirmed to be 
associated with T2D [34]. Eight of these are expressed in the β-cells and 
known to be involved in insulin secretion and in the response to increased 
IR and obesity. One gene is involved in regulating insulin sensitivity, 
another in glucose transport and two are related to obesity. The functions of 
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the other genes are still unknown [35]. Interestingly, transcription factor 7-
like 2 (TCF7L2), a nuclear receptor for β-catenin, is identified as a risk factor 
for non-alcoholic fatty liver disease (NAFLD) and a predictor of hepatic IR. 
This polymorphism also modulates a fat-induced increase in circulating 
markers of hepatocyte apoptosis in non-alcoholic steatohepatitis (NASH) 
[36].  
 
The latter finding of a gene variant associated with T2D and related to 
NAFLD and NASH, further strengthen the connection between hepatic 
metabolism, hepatic IR and T2D development. Together with our 
knowledge about sex differences in hepatic fuel metabolism, it may be 
postulated that the liver has a crucial role in a possible sex-specific 
development of IR. To improve the prevention and treatment of hepatic IR, 
a better understanding of the mechanisms behind the sex-specific hepatic 
metabolism (through investigation of pathways leading to the development 
of IR) is needed. Studies in human liver are limited since liver biopsies 
cannot be routinely taken due to the risk of complications. However, with 
the use of suitable animal models these investigations can still be 
performed. 
 
 
1.2 The liver 
 
The liver is a key metabolic organ. It is the primary organ affected by the 
nutrients and other substances which make the liver a major part of fuel 
metabolism. The main functions of the liver are storage of glycogen and 
release of glucose, ketone bodies and lipoproteins [37], i.e. maintenance of  
carbohydrate and lipid homeostasis. Other important functions of the liver 
include detoxification, immune response and storage of vitamins. 
 
This key metabolic organ has adopted the different metabolic needs in men 
and women, and therefore responds in a sex-specific manner to various 
stimuli. The sexual dimorphism of the liver involving steroid and drug 
metabolism has been recognized for several decades [38, 39]. Early studies 
established that growth hormone (GH), acting via a sex-dependent pattern of 
pituitary hormone secretion, is a major player in establishing and maintaining 
the sexual dimorphism of hepatic gene transcription that emerges in rodents at 
puberty [40, 41]. These patterns are ultimately determined by neonatal 
exposure to testosterone, which imprints the male program of neuroendocrine 
control of the pulsatile pituitary GH secretion that is first seen at puberty and 
continues through adulthood [42]. If such an androgen re-programming does 
not occur, the secretion pattern will remain as the feminine pattern 
(continuous). The sex differences in GH secretion pattern are most marked in 
rats, but are also evident in mouse [43] and humans [44, 45]. During more 
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recent years, novel technologies have been used to describe hepatic sex 
differences – at least 20% of all hepatic genes have a sex-specific expression 
pattern [46].  
 
 
1.2.1 Metabolism 
 
1.2.1.1 Carbohydrates 
Glucose is the carbohydrate that is most commonly utilized for energy 
production in mammals. The brain needs glucose continuously and too low 
concentrations of glucose in the blood can result in seizures and death. On 
the other hand, severely elevated levels of blood glucose can lead to tissue 
damage. Blood glucose levels are therefore carefully maintained (glucose 
homeostasis). This is accomplished by a strict hormonal system regulating 
glucose uptake by peripheral tissues and glucose production by the liver. 
After a meal, blood glucose levels increase and insulin plays a major role in 
keeping the blood glucose levels in balance, usually between 4-7 mM. The 
β-cells of the pancreas respond to increasing glucose levels by releasing 
insulin into the blood. During fasting, liver glycogen is broken down to 
glucose by glycogenolysis and released into the circulation. Following 
prolonged fasting, glycogen is depleted and there is an increased synthesis 
of glucose (gluconeogenesis) in the liver from amino acids and glycerol.  
 
The key enzymes controlling the gluconeogenic pathway are 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase 
(G6Pase). These enzymes are regulated by the substrates and hormones 
available at that time (mainly insulin, glucagon and glucocorticoids). In 
times of fasting, stress or exercise; glucagon and/or glucocorticoids induce 
these enzymes in order to stimulate hepatic glucose production and release. 
On the contrary, insulin inhibits gluconeogenesis by suppression of these 
enzymes. Overexpression of either PEPCK or G6Pase in animal models 
have shown to increase the rate of gluconeogenesis, resulting in 
hyperglycemia and IR [47]. In patients with T2D, the rate of hepatic 
gluconeogenesis is considerably increased compared with control subjects, 
thereby contributing to the characteristic fasting hyperglycemia in diabetes 
[48]. 
 
1.2.1.2 Lipids 
There are five major groups of lipoproteins: chylomicrons, very low-density 
lipoproteins (VLDL), intermediate-density lipoprotein (IDL), low-density 
lipoprotein (LDL) and high-density lipoprotein (HDL). Dietary fat is digested 
and absorbed by the intestine and released into the circulation as 
triglyceride-rich chylomicrons. Mature chylomicrons are formed in the 
intestinal mucosa following the absorption of the products of fat digestion. 
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These large lipoproteins enter the blood via the lymphatic ducts and are 
transported to peripheral tissues such as the adipose tissue for storage and 
the liver for break down. In a fasted state, lipolysis in the adipose tissue 
results in the release of non-esterified fatty acids (NEFA) which are 
transported and taken up by the liver and other tissues. In the liver, the 
NEFA will either be oxidized for energy production or re-esterified to form 
triglycerides (TG). The lipid oxidation takes place in the mitochondria or 
the peroxisomes. The energy produced by FA oxidation is one of the major 
energy sources for gluconeogenesis. In times of prolonged starvation, 
ketone bodies can be produced by FA oxidation and serve as fuel for the 
brain (instead of glucose). Key factors controlling FA oxidation are 
carnitine palmitoyltransferase I (CPT-1) and malonyl-coenzyme A (CoA). 
CPT-1 is an important regulator for the entry of FA into the mitochondria 
which is inhibited by malonyl-CoA, a substrate for lipogenesis. Re-
esterification of NEFA produces TG which are stored in the liver. The 
triglycerides also serve as a component of VLDL, synthesized by the liver.  
The liver also synthesizes FA and cholesterol. A key enzyme for FA 
synthesis is the acetyl-CoA carboxylase (ACC), which in response to insulin 
converts acetyl-CoA (involved in glycolysis and amino acid catabolism) to 
malonyl-CoA. Fatty acid synthase (FAS) condensates both acetyl-CoA and 
malonyl-CoA to form long chain fatty acids (LCFA). To form cholesterol, 
acetyl-CoA is converted to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). 
The rate-limiting enzyme HMG-CoA reductase then converts HMG-CoA 
into malonate that will be further processed into cholesterol [49, 50]. 
 
Triglycerides from both chylomicrons and VLDL are hydrolyzed by lipases 
that enable free fatty acids to be supplied to peripheral organs through 
membrane-associated FA transporters. There are at least five potential FA 
transporters identified, including fatty acid translocase (FAT/CD36), fatty 
acid binding protein (FABP) and fatty acid transporter protein (FATP). 
Once in the cell most FAs are noncovalently bound to proteins like FABP 
and affecting several different metabolic processes. Some of these processes 
involve regulation of gene transcription leading to changes in cell growth 
and metabolism [48, 51, 52]. Previous studies have shown that the up-take of 
LCFA and their incorporation to TG are higher in female livers than in male 
[53]. These observations can be linked to the concentration of FAT/CD36 and 
FABPs, which are higher in female livers [54]. Also, female rats secrete more 
very-low-density-lipoproteins [55]. 
 
Transcription factors such as PPARα, LXR and SREBP-1c are also 
important regulators of lipid metabolism, controlled by different FAs and 
have been described to also be involved in the regulation of gluconeogenesis 
[56-58]. PPARα is activated by FAs released in the fasting state, leading to 
increased hepatic β-oxidation and gluconeogenesis [59]. Estrogens have been 
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shown to inhibit the actions of PPARα in obesity and lipid metabolism 
through its effects on PPARα-dependent regulation of its target genes [60].  
 
1.2.1.3 Amino acids 
Dietary amino acids (AA) are taken up by the liver via the portal vein, for the 
purposes of oxidative metabolism, protein synthesis and/or gluconeogenesis, 
they are not stored or excreted intact. The primary metabolic fate of AA  is 
their conversion to glucose [61] as a substrate for energy production in the 
brain and peripheral tissues. Amino acids such as alanine and cysteine are all 
converted into pyruvate through different processes like transamination [62, 
63]. Pyruvate serves as a substrate for gluconeogenesis, lipogenesis and 
ketogenesis. By transamination, amino groups are transferred to alpha-
ketobutyrate to create glutamate and keto acids. Glutamate transports nitrogen 
to the urea cycle where it is oxidized and energy produced. 
 
 
1.2.2 Sex- different response to metabolic stressors 
 
1.2.2.1 Absorptive state 
The absorptive state (postprandial) is the period during which ingested 
nutrients enter into the circulation and supply the body with energy. Glucose 
is the major energy source and some of it is converted to glycogen, stored in 
skeletal muscle and liver. In adipose tissue, glucose is transformed and stored 
as fat. However, a report shows that women have a higher rate of nutrients 
appearance than men after a meal and therefore show higher levels of plasma 
glucose. No differences in insulin or hepatic glucose production have been 
observed at this time point [64]. This might be explained by the greater 
muscle mass in men which is correlated to increased glucose uptake. In the 
same absorptive state, women have lower levels of plasma TG than men [65]. 
This sex-difference may be explained by the fact that adipose lipolysis after a 
meal is more suppressed in women, especially in the upper body 
subcutaneous depots. In the adipose tissue, insulin stimulates lipoprotein 
lipase (lipid uptake) and inhibits hormone sensitive lipase (lipolysis). Thus, 
women might be more insulin sensitive and thus have suppressed lipolysis at 
this time point. As mentioned above, men store more dietary fat in the upper 
body whereas women tend to have more in the lower body, thus resulting in a 
sex-specific body composition. Postprandial VLDL production is decreased 
in both men and women. However, the basal VLDL production is higher in 
women [10]. Most of the dietary amino acids are used in protein synthesis or 
oxidized and used for energy production.  
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1.2.2.2 Post-absorptive state 
The post-absorptive state is the period during which the gastric intestinal (GI) 
tract is empty of nutrients and the body utilizes stored energy. The metabolic 
homeostasis at this state is entirely maintained by the interplay in uptake and 
release of metabolites in the different metabolic organs. The plasma levels of 
most metabolites are similar between the sexes. However, men and women 
seem to have different approaches to maintain the homeostasis. Women 
utilize more stored fat as energy source compare to men who primarily use 
carbohydrates and amino acids. After an overnight fast, women have higher 
levels of NEFA and ketone bodies than men [64] and the rate of VLDL 
production and secretion is also higher in females [10].  
 
 
1.3 Hormonal regulation of hepatic gene expression 
 
1.3.1 Steroid hormones 
 
1.3.1.1 Estrogen 
The female sex hormone estrogen is mainly synthesized in the ovaries from 
the granulose (theca) cells through the synthesis of androstenedione from 
cholestreol. The enzyme aromatase catalyzes the last step in the formation of 
estrogens from androgens [66]. There are three major forms of the hormone: 
estrone (E1), estradiol (E2), and estriol (E3). Estradiol (E2) is the most potent 
ligand and the predominant form in fertile women. A minor part of the total 
estrogen produced is synthesized at extragonadal sites such as the brain, liver, 
bone and adipose tissue [67]. However, in postmenopausal women and men, 
this amount of estrogen (mainly E1) can constitute a significant part of the 
total estrogen produced. Several studies show that the aromatization of 
androgens to estrogens is increased with age and obesity [68]. The aromatase-
knockout (ArKO) mouse cannot produce estrogen and as a consequence, have 
increased intra-abdominal adipose tissue. Also, the ArKO mice develop a 
fatty liver phenotype which may be related to increased levels of cholesterol 
[69]. It has also been reported that estrogens increase the activity of 
cholesterol 7α-hydroxylase (Cyp7a1), the rate-limiting enzyme in bile acid 
synthesis, in rat hepatocytes [70]. Moreover, mice deficient in the oxysterol 
receptor LXR (LXR−/−) fail to induce transcription of the Cyp7a1, and thereby 
also accumulate cholesterol in the liver [71]. Another study reports 
impairment in hepatic FA β-oxidation in an aromatase-deficient mouse 
model. Analyses revealed a decrease in both mRNA expression and  activities 
of specific enzymes (medium chain acyl CoA dehydrogenase (MCAD), very 
long-chain acyl-CoA synthetases (VLACS), AOX and catalase) required in 
FA β-oxidation [72].  
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There are two estrogen receptors: ERα and ERβ [73, 74]. Ligand-activated 
ERs dimerize and bind directly to estrogen response elements (ERE) [75] or 
indirectly to other response elements [76]. Depending on the relative 
abundance and binding affinities of co-regulators, ERs can activate or inhibit 
target gene expression. Both male and female ERα knockout (ERαKO) mice 
develop IR and impaired glucose tolerance [77], similar to humans lacking 
ERα [78] or aromatase [79]. The IR in ERαKO mice is largely localized to 
the liver [80], including increased lipid content and hepatic glucose 
production. Genes involved in hepatic lipid biosynthesis are up-regulated, 
while genes involved in lipid transport are down-regulated in these animals. 
The hepatic gene expression of the leptin receptor is also lower while the 
adiponectin concentration was decreased in the ERαKO mice [80]. 
Interestingly, the expression of lipogenic genes was decreased in diabetic 
Ob/Ob mice after E2 treatment, supporting a connection between glucose 
tolerance and the expression of lipogenic genes in the liver [81, 82]. Also, in 
the livers of high-fat diet fed female mice treated with E2, reduced expression 
levels of the hepatic key lipogenic gene SCD1 was observed. This was 
accompanied by decreased hepatic TG content. Importantly, E2 decreased the 
hepatic expression of G6Pase [83]. Evidently, estrogens and ER play 
important roles in hepatic lipid and glucose homeostasis. 
 
 
 
Figure 1. Overview of the actions of selected hormones on hepatic 
carbohydrate and lipid metabolism. 
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1.3.1.2 Testosterone 
Testosterone (17-hydroxy-4-androsten-3-one) is one of the most prevalent 
androgens and belongs to the steroid hormone superfamily. Naturally 
synthesized testosterone is primarily produced from the Leydig cells of testes 
while a small amount comes from the adrenal glands. The secretion of the 
hormone is controlled by the hypothalamic-pituitary-testis axis (reproductive 
hormone axis) [84]. Secreted testosterone binds and activates the intracellular 
androgen receptor (AR), a member of the nuclear receptor superfamily that 
functions as a ligand-activated transcription factor [85]. Once activated, AR 
translocates into the nucleus where it dimerizes and regulate gene 
transcription either by direct binding to the androgen response element (ARE) 
on the target gene promoter, or indirect by interacting with other transcription 
factors [86]. 
 
As mentioned earlier, testosterone is important for the imprinting of the male 
endocrine program, including the pulsatile pituitary GH [42]. A recent study 
supports the notion that neonatal testosterone exposure contributes to the 
remodeling of the GH axis and defeminizing hepatic steroid-metabolism, 
emphasizing the indirect impact of testosterone on hepatic function. 
Testosterone treatment in newborn female mice results in imprinting of 
different GH-dependent and sex-specific hepatic genes. The male-
predominant genes Cyp2d9 and MUP 1/2/6/8 were not masculinized after 
treatment, but two female-predominant genes, Cyp2b9 and Cyp2a4, were 
defeminized [87].  
 
Hepatic AR-knockout (ARKO) male mice (H-AR−/y), fed a high-fat-diet, 
developed hepatic steatosis and IR [88], suggesting that AR plays an 
important role in preventing such metabolic disorders. H-AR−/y mice show 
decreased expression of peroxisome proliferator-activated receptor α 
(PPARα), genes for fatty acid (FA) β-oxidation and FA oxidation rates, 
increased levels of sterol regulatory element binding protein 1c (SREBP1c) 
and genes for de novo lipid synthesis and hepatic content of TG. However, 
female ARKO mice do not have this phenotype [88]. Higher levels of 
estrogens in female animals and ERα-dependent effects on hepatic lipid 
metabolism might contribute to this sex-difference.  
 
 
1.3.2 Peptide hormones  
 
1.3.2.1 Growth hormone 
Growth hormone (GH), also called Somatotropin, is a polypeptide mainly 
secreted from the somatotrophs within the anterior pituitary gland. The 
synthesis of the hormone is regulated by GH-releasing hormone (GHRH). 
The secretion of GH is regulated by the antagonists: GHRH and GH-releasing 
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inhibiting factor (somatostatin) [89]. However, the balance of these 
stimulating and inhibiting peptides is in turn affected by many physiological 
stimulators (e.g. exercise, nutrients, sleep and sex hormones) and inhibitors 
(e.g. glucocorticoids, IGF-1 and GH itself by negative feedback) [90-93]. The 
release of GH into the circulation is characterized by a pulsatile pattern which 
is sex-specific, especially in rats. In male rats, the GH secretion is more 
pronounced with distinct peaks every 3-5 hour intervals. In contrast, the GH 
secretion in female rats are continues with only small changes in plasma 
concentration [94, 95].  
 
GH binds to its receptor (GHR) and promotes homodimerization of the 
receptor forming the GH-GHR complex which in turn associates the 
intracellular Janus Kinase 2 (JAK2). Two associated JAK2 molecules activate 
each other by trans-phosphorylation leading to phosphorylation of the GHR 
on multiple tyrosine residues providing docking sites for other signaling 
molecules of different pathways [96]. The most well studied intracellular 
pathway involves the signal transducers and activators of transcription 
(STATs). 
 
One of the most prominent effects of GH is to promote postnatal longitudinal 
growth in bone [97]. Nevertheless, GH has also been shown to influence a 
wide range of other important physiological processes in the body. The 
hormone is known to impact the regulation of metabolism, cell differentiation 
and maintenance of the immune system [96, 98]. The liver was the first organ 
identified as a target for GH [96], but today we know that many organs 
express GHR. In muscle, GH promotes increase in muscle mass by 
stimulating protein synthesis and amino acid uptake [99]. The effects of GH 
in adipose tissue includes stimulation of lipolysis and inhibition of lipoprotein 
lipase activity [100].  Thus, GH is an anabolic hormone that reduces fat mass 
and increases lean muscle mass. The liver is also a major target for GH. The 
hormone has effects on hepatic glucose, lipid, amino acid and drug 
metabolism and the sex-specific secretion pattern has shown to have a great 
impact on the hepatic transcriptional regulation. Several transcription factors 
(TF) have been identified as the mediators of this regulation, leading to the 
GH-dependent sex-specific hepatic gene expression [101, 102]. These TFs 
include; STAT5b, HNF4α, HNF6 and HNF3β which all are involved in the 
regulation of the sex-specific CYP genes. In male liver, STAT5b is directly 
activated by the GH secretion pattern, which also activates the HNF4α. 
STAT5b binding sites have been found in the promoter of e.g. suppressor of 
cytokine signaling 2 (SOCS2) [103] and several male-specific CYP genes in 
rat, including Cyp2c12, Cyp2c11, Cyp2a2 and Cyp4a2. In female liver, 
HNF6 and HNF3β are increased by the continuous GH secretion pattern 
[104]. The binding of those two TFs to specific promoters have been shown 
to induce the expression of for example Cyp2c12. HNF4 and HNF3β have 
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been shown to regulate genes involved in glucose and lipid metabolism, 
hence the GH effects on metabolism could be via these TFs [105, 106]. In 
rats, at least 30% of hepatic sex differences are explained by the female-
specific secretion of GH, through the induction of female-predominat 
transcripts and suppression of male-predominant [107]. Continuous 
administration of GH has been shown to increase hepatic expression of 
SREBP-1c and its downstream target genes [108, 109], as well as hepatic 
TG synthesis and VLDL secretion [110, 111]. Furthermore, PPARα which 
is male-predominant in rat liver has been shown to be suppressed by 
continuous GH infusion in hypophysectomized [112] or old [109] rats and 
by GH treatment in cultured rat hepatocytes [113]. 
 
Sex-dependent expression and GH regulation also characterizes other 
families of genes involved in steroid or xenobiotic metabolism, such as the 
sulfotransferases and class α and μ glutathione- S-transferases (GST) [114]. 
 
 
Animal model Investigated 
sex 
Effects on hepatic metabolism 
 
Reference 
Lipid Carbohydrate 
ERKO (ERα-/-) both ↑ Lipid content 
↑ Lipogenesis 
↑ HGO Heine [115] 
Bryzgalova 
[80] 
ArKO (-/-) males ↑ Lipid content 
↓ FA oxidation 
 Nemoto [72] 
ARKO (H-AR−/y) 
 
males ↑ Lipid content  
↑ Lipogenesis 
↓ FA oxidation  
↑ Lipogenesis  
 Lin [88]  
LIRKO (IR-/-) 
 
both   ↑ HGO Fisher [116] 
Michael [117] 
GHRKO (Ghr-/-) males ↑ Lipid content 
↑ Lipogenesis  
↓ Lipid output  
 Fan [118] 
db/db (Lepdb/db) both ↑ Lipogenesis  Tartaglia 
[119] 
Sahai [120] 
 
Table 1. Effects of important hepatic hormone receptors on hepatic fuel 
metabolism in rodents. 
Liver-specific knock-out: LIRKO, ARKO and GHR KO. 
Whole-body knock-out: ERKO and ArKO. 
Natural mutation: db/db. 
Estrogen receptor α knock out (ERKO), Aromatase receptor knock out (ArKO), 
Androgen receptor knock out (ARKO), Liver-specific insulin receptor knock out 
(LIRKO), Growth hormone receptor-knock out (GHR KO). 
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1.3.2.2 Leptin 
Leptin was first identified after cloning of the mouse and human Ob gene in 
1994 by Friedman et al [121]. The hormone is one of several adipokines (e.g. 
TNF-α, IL-6, PAI-1, RBP4) and mainly secreted from white adipocytes. 
However, several studies show that leptin also can be synthesized in other 
tissues such as placenta, skeletal muscle and activated stellate cells [122].  
 
Leptin acts primarily on the hypothalamus to modulate food intake, energy 
expenditure and whole-body energy balance [123, 124]. Originally, the 
function of leptin was thought to only involve prevention of obesity because 
leptin-deficient ob/ob mice and leptin-resistant db/db mice are obese. 
However, decreased levels of leptin are crucial for metabolic adaptation to 
starvation [125, 126]. Leptin is also important for the onset of puberty by 
accelerating the maturation of the reproductive axis [127]. The expression of 
leptin is known to be regulated by several different factors such as 
glucocorticoids [128-130], insulin [130] and fatty acids [131].  
 
The OB receptor (OB-R) was cloned in 1995 by Tartaglia et al [119] and so 
far, the leptin receptor (OB-R) is known to be spliced into six isoforms (OB-
Ra, OB-Rb, OB-Rc, OB-Rd, OB-Re and OB-Rf) [132]. However, the OB-
Rb appears to account for the majority of leptin actions [133, 134]. OB-Rb 
activates the JAK/STAT-signaling pathway (JAK2/STAT3) [135], affecting 
expression of hypothalamic neuropeptides, thus regulating food intake. The 
soluble isoform (OB-Re) is a serum leptin-binding protein. Leptin circulates 
as a free form or OB-Re-bound form, and the sum of the two is generally 
measured as the total leptin level [136]. 
 
In healthy humans, the circulating level of leptin is higher in women than in 
men [137]. This sex-difference can be explained by the differences in body 
composition and sex hormones. Women have more subcutaneous fat depots, 
which is known to produce more leptin, compared to men, who tend to have 
more visceral fat [138]. Leptin is significantly elevated in obese compared to 
normal weight humans and rodents [139-141]. Also, experimental data 
support the idea that testosterone exerts a negative influence on leptin levels 
in both humans and rodents. Low leptin levels are associated with 
androgenicity in non-obese men and women [142]. In obese subjects, 
elevated concentration of circulating leptin fails to promote weight loss. 
This phenomenon is referred to as “leptin resistance”, the mechanism is 
today not clear [143, 144]. Suppressor of cytokine signaling 3 (SOCS3) 
[145, 146] and an increase in serine phosphorylation of Jak2 have been 
shown to contribute to the blockade of leptin action [147]. In addition, the 
oxidative stress that is correlated to obesity has also recently been shown to 
be a contributing factor to leptin resistance [148]. 
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In the liver, leptin is known to stimulate FA oxidation and prevent the 
accumulation of lipids by inhibiting the expression of SREBP-1 [149]. In 
ob/ob mice, leptin has also been shown to repress hepatic mRNA levels and 
enzymatic activity of SCD1, which is important in the biosynthesis of 
monounsaturated fatty acids. ob/ob mice with mutations in SCD1 had 
histologically normal livers with significantly reduced triglyceride storage and 
VLDL production [123]. A recent study show that leptin treatment in male 
diabetic ob/ob mice, induce the hepatic mRNA expression of insulin growth 
factor binding protein (IGFBP) 2 independently of its ability to alter body 
weight. This induction of IGFBP2 significantly improved the insulin 
sensitivity, glucose tolerance and hepatic glucose production [150], 
implicating a new therapeutic regime for T2D. 
 
1.3.2.3 Insulin 
In year 1921, scientists Banting and Best discovered insulin, a hormone 
produced and secreted from pancreatic β-cells of Langerhan´s islands in 
response to increased blood glucose after digestion of food [151]. Most cells 
of the body have insulin receptors attached to its surface to which insulin 
can bind and initiate an intracellular signalling cascade. Binding of insulin 
to its receptor results in the activation of two main pathways: (a) the 
phosphatidylinositol 3-kinase (PI3-kinase) pathway and (b) the mitogen-
activated protein kinase (MAPK) cascade [48].  
 
The insulin receptor is a heterodimeric receptor with intrinsic tyrosine 
kinase activity, which undergoes a conformational change in response to 
insulin binding. Upon ligand binding, the kinase is activated and 
phosphorylation of several tyrosine residues within the cytoplasmic domain 
of the receptor takes place. Activation and tyrosine phosphorylation of the 
receptor leads to the recruitment of several docking molecules including 
insulin receptor substrate proteins (IRS) 1-4. These interactions result in a 
spectrum of intracellular responses by activating downstream adaptor 
molecules such as p85 regulatory subunit of PI3-kinase and growth factor 
receptor-bound protein 2 (Grb2). The activation of PI3-kinase leads to 
phosphorylation of Akt (also konown as protein kinase B) at different sites 
(Ser, Thr). Insulin-dependent stimulation of e.g. glycogen synthesis occurs 
through Akt-dependent phosphorylation (inactivation) of glycogen synthase 
kinase 3 (GSK-3), an inhibitor of glycogen synthase, leading to enhanced 
glycogen synthase activity. This is one example of how this signaling 
pathway regulates glucose, lipid and protein turnover [48, 152-154]. 
Activation of the MAPK pathway results in the activation/phosphorylation 
of specific transcription factors regulating cell proliferation and 
differentiation [48]. Liver insulin receptor knockout (LIRKO) mice display 
severe hepatic IR and a failure of insulin to suppress hepatic glucose 
production and to regulate hepatic gene expression [116, 117]. This observed 
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hepatic IR in the LIRKO mice leads to hyperinsulinemia and secondary extra-
hepatic IR. 
 
In liver, insulin stimulation results in enhanced utilization and storage of 
glucose as lipid and glycogen while repressing glucose release and synthesis 
by inhibiting the key enzymes for gluconeogenesis (PEPCK and G6Pase) 
[48] and VLDL production [155, 156]. The transcription factor SREBP is 
known to up-regulate genes involved in lipogenesis and down-regulate FA-
oxidation in response to insulin [157, 158]. Other transcription factors like 
Insulin-response element binding protein-1 (IRE-BP1) and FoxO1 are 
regulated by insulin signaling via Akt-mediated phosphorylation. IRE-BP1 
inhibits the expression of specific gluconeogenic genes and genes involved in 
FA oxidation. The transcription factor FoxO1 mediates negative effects of 
insulin [159] on hepatic gluconeogenesis.  
 
Phosphorylation by Akt results in the sequestration of FoxO1 in the 
cytoplasm, leading to reduced expression of its target genes. The opposite is 
the case for IRE-BP1, where impaired Akt signaling leads to cytoplasmic 
sequestration and de-regulated gene expression of target genes [160]. Taken 
together, hepatic IR leads to decreased hepatic glucose uptake, increased 
VLDL production and increased glucose production and output. 
 
 
1.4 Oxidative stress 
 
Oxidative stress is caused by a disturbance in the balance between the 
antioxidant defense capacity of the body (reduced) and the production of 
reactive oxygen species (ROS) (increased). This imbalance is closely 
associated with a number of diseases including cancer, neurodegenerative 
diseases, cardiovascular diseases and diabetes [161].  
 
Endogenous ROS can be produced from many systems in cells including the 
mitochondrial respiratory chain [162], the cytochrome P450s [163, 164], 
oxidative enzymes such as xanthine and monoamine oxidase (MAO), the 
NADPH oxidase complex [165], autooxidation of heme proteins such as 
ferrohemoglobin and myoglobin or substances such as catecholamines. In 
addition, ROS levels can be increased by environmental sources including 
radiation, UV light, smoke and chemicals [166]. 
 
The mitochondrial respiratory chain normally produces superoxide (O2-) and 
peroxide (O22-) that are necessary for cellular functions. Excess superoxide is 
neutralized by endogenous antioxidants and antioxidant enzymes. However, 
superoxide can be converted to hydrogen peroxide (H2O2) which can produce 
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extremely reactive hydroxyl radicals (OH-) which cannot be eliminated by an 
enzymatic reaction [162].  
 
Because ROS production is a naturally occurring process, a variety of 
enzymatic and non-enzymatic mechanisms have evolved to protect cells 
against ROS (Yu 1994). Protective enzymes include the superoxide 
dismutases (SODs) that remove O2-; catalase and the GSH peroxidase 
system that remove H2O2; glutathione transferases that can remove reactive 
intermediates and lipid aldehydes, metallothioneins, heme oxygenase, 
thioredoxin that remove various ROS. The non-enzymatic protection 
includes low molecular weight antioxidants such as GSH itself, vitamin E, 
ascorbate (vitamin C), retinol (vitamin A), ubiquinone, uric acid and 
bilirubin [167, 168]. 
 
 
1.4.1 Obesity-induced diabetes 
 
Several mechanisms have been proposed to cause oxidative stress and 
consequently the development of IR and T2D in animal models and humans 
[169]. An increase in the production of ROS has been associated with fat 
accumulation in the liver subsequently leading to non-alcoholic fatty liver 
disease (NAFLD) and hepatic IR [170], see figure 2 [171].  
 
The exact mechanism for the increased ROS production in the liver is not 
clear but an increased uptake of NEFA by the hepatocytes might lead to 
mitochondrial β-oxidation overload which may exhaust the antioxidant 
defense (including GSH and glutathione transferases) and induce oxidative 
stress. Schulman and co-workers have demonstrated that intracellular 
accumulation of TG and FA intermediates in muscle and liver is associated 
with IR in humans [172] and that mitochondrial dysfunction leads to 
decreased FA β-oxidation and fat accumulation in skeletal muscle or liver 
[173]. Also, ROS have been shown to induce various signaling pathways 
involving FoxO1, MAPK, JAK/STAT, p53, phospholipase C and PI(3)K. 
For example, ROS-induced hepatic IR has been shown to be mediated via 
JNK [170], known to be activated by oxidative stress [174]. 
 
 
1.5 Metabolite profiling in metabolic disease 
 
Metabolites are the building blocks for all other biochemical substrates and 
structures including genes, transcripts and proteins. Metabolites are defined 
as low molecular-weight compounds (LMC) and can either be organic or 
inorganic. The LMC are the reactants, intermediates or products of enzyme 
mediated biochemical reactions. General classifications of metabolites 
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involve molecular weight, polarity and structure or reaction similarity. The 
most frequently applied method is similarity where metabolites are 
classified according to chemical core structure (e.g. amino acids) or by 
involvement in the same metabolic pathway (e.g. glycolysis). In contrast to 
genomics, transcriptomics and proteomics, metabonomics is a newly 
developed technique that has been described as the recognition and 
measurement of the entire metabolic reaction of an organism in response to 
internal or external influences [175]. Metabolites are intermediates in 
signaling pathways that can regulate gene expression [176]. For example, 
FAs act as ligands for several of the PPAR nuclear receptors in the liver. 
Metabolite abundance reflects a biological response to exogenous and 
endogenous inputs, and when investigating pathways from genotype to 
phenotype, metabolites can provide a powerful complement to gene 
expression data and give novel insights into disease pathogenesis 
mechanisms (see figure 3). It is regarded as a diagnostic tool that is useful 
for metabolic classification of individuals. The great asset of this technique 
is that it involves the quantitative, noninvasive analysis of easily sampled 
human body fluids such as urine, blood and saliva. Analysis of tissue 
extracts is also possible. 
 
 
 
 
 
Figure 2.  Proposed model for the development of hepatic IR in NAFLD.  
Remodeled from Cusi, 2009 [171].  
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1.5.1 Serum metabolites 
 
Measurement of blood glucose levels is a standard procedure in the diagnosis 
of metabolic disease such as T2D. Elevated levels may indicate 
hyperglycemia due to peripheral IR and impaired glucose uptake, or increased 
hepatic glucose output due to hepatic IR. Similarly, altered levels of other 
metabolites in plasma may reflect the metabolic profile of the whole-body or 
a specific tissue. During the last decade, metabolic profiling of body fluids 
has emerged as a research tool for the search of biomarkers which can 
potentially be used for prevention and/or to follow responses to therapeutic 
interventions. A recent study demonstrated the potential of such a technique. 
Plasma profiles of subjects with NAFLD and NASH, generated using an 
untargeted global metabolomic analysis, were used to identify disease-
specific LMC patterns and candidate biomarkers [177]. 
 
 
1.5.2 Liver-derived metabolites 
 
Metabolites derived from the liver may predict the metabolic state of the 
organ. Thus, liver-derived metabolites may be of importance for diagnosis of 
metabolic disorders related to the liver. For example, several reports link 
changes in the levels of hepatic oxidative stress and circulating amino acids to 
T2D. In a recent study, metabolite profiles of plasma demonstrates elevated 
levels of several amino acids such glutamate, lysine, tyrosine, and isoleucine 
in human subjects with steatosis and/or NASH [177]. The higher level of 
glutamate in plasma is speculated to be due to increased transamination of 
amino acids being degraded in the liver. The human serum metabolome has 
also been shown to depend on e.g. age and sex [178]. Whether age- or sex-
related differences in hepatic metabolism can be revealed using 
metabolomics is yet to be determined. 
 
Ophthalmate 
The tri-peptide ophthalmate (glutamate-2-aminobutyrate-glycine) has been 
proposed as a biomarker for oxidative stress. By determining metabolic 
profiles through capillary electrophoresis time-of-flight mass spectrometry 
(CE-TOFMS), Soga et al. detected global changes in metabolite levels in 
the liver and serum of acetaminophen (AAP)-treated male mice (analgesic). 
Significant increases in ophthalmate levels after treatment were observed.  
Because of its function as a sensitive indicator of hepatic glutathione (GSH) 
depletion, ophthalmate was identified as a biomarker that can reveal acute 
liver injury [179, 180]. Ongoing clinical investigations will determine the 
usefulness of measuring the concentration of plasma GSH and ophthalmate 
in patients with various liver diseases [180].  
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Betaine 
Betaine is a well-studied metabolite known to protect against the development 
of hepatic steatosis in animal models [181]. Betaine has been shown to reduce 
toxic levels of homocysteine (Hcy), a marker for many diseases including 
cardiovascular disease (CVD) [182]. It has also been shown that 
supplementation of betaine to high-carbohydrate (sucrose) diet-fed male mice 
decreased hepatic fat accumulation. This was mediated by direct activation of 
the hepatic AMP-activated protein kinase (AMPK) system and subsequent 
inhibition of de novo lipogenesis in the liver [183]. An improvement of 
hepatic steatosis and IR due to betaine supplementation has also been reported 
in male mice fed a high-fat diet for 12 weeks [184]. In a long-term moderate 
high dietary fat model of NAFLD in mice, betaine treatment prevented and 
treated the condition of fatty liver. Betaine also significantly improved the 
hepatic IR by increasing the activation of IRS1, with resultant improvement in 
downstream signaling pathways [185]. Interestingly, the control of betaine 
metabolism has been shown to differ between male and female non-diabetic 
patients [186]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Omics organizational relationship.  
General schematic of the “-omics” organisation where the flow is from genes to 
transcripts to proteins, with metabolites being the link to phenotype. Metabolite 
abundance reflects a biological response to stimuli and when investigating 
pathways from genotype to phenotype, metabolites can provide a powerful 
complement to gene expression data and give novel insights into disease 
pathogenesis mechanisms 
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2 AIMS 
 
The general goal of this thesis was to investigate if there is a relationship 
between sex differences in hepatic fuel metabolism and the development of 
insulin resistance. 
 
To achieve this goal, more specific aims were formulated: 
 
A. To characterize sex differences in lipid and carbohydrate metabolism 
in rat liver.  
 
B. To investigate the effects of short-term high-fat feeding on hepatic 
metabolism and insulin sensitivity in rats.  
 
C. To investigate if differences in liver functions could provide clues to 
sex-different development of insulin resistance and glucose 
intolerance in Zucker diabetic fatty (ZDF) rats.  
 
D. To determine the extent of which sex differences in hepatic gene 
expression are translated into sex-different levels of low molecular-
weight compounds. 
 
E. To evaluate the effects of testosterone treatment on glucose and lipid 
metabolism in male ZDF rats. 
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3 METHODS 
 
This section gives a general commentary of some of the methods used in our 
studies presented in this thesis. More detailed descriptions of the separate 
methods can be found in the material and methods sections of paper I-IV. 
 
3.1 Animals 
 
The Zucker diabetic fatty (ZDF/Gmi™-fa) rat has become a widely used 
animal model for studying T2D. The Zucker diabetic fatty (ZDF) rats have a 
mutation in the fa gene which results in impaired leptin receptor signaling, 
obesity and IR. However, male and female rats of this strain show differences 
in the development of T2D. The males spontaneously develop hyperlipidemia 
and hyperglycemia by 8 weeks of age and diabetes by 12 weeks whereas the 
females only become diabetic when fed a diabetogenic (high-fat) diet [187].  
The mechanistic reasons for this sex-different phenotype is not clear, thus 
further studies are requested. In paper III, we wanted to investigate the sex-
different development of T2D, and therefore we used the ZDF rats as a 
model. 
 
 
3.2 Transcript profiling 
 
3.2.1 Microarray 
The microarray methodology is used to determine transcript profiles. The 
microarray technique was developed in the late 1990s and is now an 
established method for gene expression analysis [188]. There are a number of 
different platforms for transcript profiling. The most common ones are 
spotted arrays and Affymetrix GeneChips® [189]. In this thesis, we used 
spotted arrays and the following description will therefore only describe the 
principles concerning that type of array. For paper I, II and III we used non-
commercial microarrays manufactured at the Royal Institutet of Technology 
(KTH), whereas in paper IV we used the commercialized Agilent platform. 
 
All experiments included in this thesis were standardized according to the 
Minimum Information About a Microarray Experiment (MIAME) [190]. 
 
3.2.1.1 Experimental design 
Due to the cost, time and amount of data that the experiment will generate, 
one of the most important parts of a microarray experiment is to address a 
specific biological question. Depending on the biological question and what 
type of samples that will be used, there are different ways of designing the 
experiment in order to achieve the best results. The design of an experiment 
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from which one wants to generate a list of differently expressed genes 
comparing two treatments (e.g. untreated vs. treated) differ from the design of 
an experiment where the aim is to study different states in a disease 
development depending on the effect of time.   
 
One of the features to consider while designing an experiment is the use of 
one- or dual-color arrays. One-color arrays will provide an absolute value of 
the expression of the analyzed sample. This provides the opportunity to more 
freely compare different groups and if desired, add more samples to the 
analysis later on. In one-color experiments, the use of dye Cy3 is mostly used 
due to its stability. A dual-color experiment results in a ratio between two 
samples that are hybridized together on the array, labeled with either Cy3 or 
Cy5 e.g. treated versus untreated. This approach is more limiting since new 
groups of samples cannot be added without altering the primary design. 
However, if you have a clear biological question and an isolated experiment, 
this approach can be more cost-efficient since two samples are analyzed at the 
same time. In all studies included in this thesis (paper I-IV) we used the dual-
color approach. The design is also depending on the type of samples. Samples 
from a cell-line are known to be more homogenous compared to human and 
animal samples from e.g. tissues which often show high individual 
differences. There are different ways to compare the different sample groups 
(direct, indirect or loop design) in order to get the best comparison.  
 
Biological replicates are important to minimize the influence of individual 
variations. Because of the large amount of transcripts that are being measured 
in each experiment, there will always be variations between individuals even 
if they are treated in the same way. Technical replicates are essential for 
minimizing the influence of sample preparation, labeling, hybridization or 
quantification. The minimum numbers of replicates that are required to except 
the statistical analysis outcome have to be considered for each individual 
experiment.  Generally, the more replicates the better, but it has been shown 
that trustworthy results can be obtained with only a few biological replicates 
[191]. In this thesis, at least four biological replicates were analyzed.  
 
3.2.1.2 RNA quality 
The quality of the RNA samples should always be checked using a 
Bioanalyzer or with a method equal to that. The Bioanalyzer consider the 
28S/18S ratio as well as the RNA Integrity Number (RIN) of the RNA sample 
[192]. The RIN had not been commercialized when we performed our first 
microarray experiments described in this thesis. For paper I-II, only the 
28S/28S ratio (>1.8) was considered, whereas for the RNA samples used in 
paper III and IV, a RIN above 8 [193] was considered acceptable for further 
analysis.  
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3.2.1.3 Labeling and hybridization 
Depending on the platform, different protocols for labeling and hybridization 
of the samples are available. In short, total RNA is amplified and incorporated 
with fluorescence-labeled nucleotides in a first strand cDNA or cRNA 
synthesis (depending on platform and protocol). The labeled samples are 
purified from unincorporated nucleotides and applied to the array for 
overnight hybridization. The hybridization normally takes place in a 
hybridization chamber put in a water bath or hybridization oven. After 
hybridization, the arrays are washed and scanned. Microarray scanners 
contain lasers that excite the fluorophores at different wavelengths. The 
scanning creates an image of the array which is used for further data analysis. 
See figure 4.  
 
For paper I, II and III we used non-commercial (generic) microarrays 
manufactured at the Royal Institute of Technology (KTH). Therefore, we 
used a labeling and hybridization protocol suitable for this purpose. In paper 
II, the effect of different high-fat diets were studied in male SD rat livers. 
Samples from control animals (standard diet) were hybridized with samples 
from rats fed a high-fat diet. In paper I, we studied the sex differences in 
healthy male and female SD rats. Samples from male rat livers were 
hybridized with female samples on individual arrays in order to get the direct 
effect of sex on hepatic gene expression. In paper III, we investigated the sex-
different development of IR in ZDF rats. To identify high-fat diet-induced 
changes, healthy females (fZDF) were hybridized together with high-fat diet 
induced diabetic (HF-fZDF) females. To find sex-dependent hepatic gene 
products that might be related to disease development, fZDF and diabetic 
males (mZDF) were hybridized together on each array. In paper IV, the 
microarray experiment was performed using the Agilent platform. The effect 
of testosterone treatment on hepatic gene expression was investigated in male 
lean and obese ZDF rats by hybridizing an individual untreated sample with 
TU-treated sample onto the array. 
 
3.2.1.4 Data analysis and statistics 
Processing of microarray data include annotation of spots, background 
correction, normalization and transformation of raw data into expression 
values.  
 
For the arrays (KTH) used in paper I, II and III, image analysis was 
performed using the GenePix software (Axon Instruments). The 
fluorescence ratios of the detected spots were normalized with the Locally 
Weighted Scatter Plot Smoother (LOWESS) method using the statistical 
language R. Identification of differentially expressed genes was performed 
using the Significance Analysis for Microarray (SAM) software developed 
at the Stanford University [194]. For the arrays in paper IV, images were 
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annotated using the Feature Extraction software developed by Agilent 
Technologies. Further data analysis and identification of significantly 
expressed genes were performed with GeneSpring, also developed by Agilent 
Technologies.  
 
A 5% false discovery rate (FDR) was used as a first cut-off. Genes with a 
greater than 1.5-fold increase or decrease were considered as being 
regulated, even though smaller changes in gene expression may also have 
important biological consequences [107]. The results are represented as the 
mean of at least three independent determinations. 
 
 
 
 
 
 
 
 
 
Figure 4. Flow chart for microarray analysis. 
Total RNA is amplified and incorporated with fluorescence-labeled nucleotides in a 
first strand cRNA synthesis. The labeled samples are purified and applied to the 
array for hybridization. After hybridization, the arrays are washed and scanned. The 
scanning creates an image of the array which is used for further data analysis 
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3.2.2 Real-time quantitative PCR 
 
There are different methods for validating the results achieved from 
microarray experiments. The most commonly used method today is real-time 
quantitative PCR. This method allows you to study the expression of a 
number of selected transcripts and compare to array data. Real-time PCR is 
more sensitive, specific and faster to perform compared to microarray. 
 
Currently, four different types of real-time PCR chemistries are available; 
TaqMan® (Applied Biosystems), Molecular Beacons, Scorpions® and 
SYBR® Green (Molecular Probes). They all detect PCR products through the 
generation of a fluorescent signal. TaqMan probes, Molecular Beacons and 
Scorpions generate the fluorescence signal via the coupling of a fluorogenic 
dye molecule and a quencher to the same or different oligonucleotides. SYBR 
Green is a fluorogenic dye that exhibits little fluorescence when in solution 
but emits a strong fluorescent signal upon binding to double-stranded DNA. 
In this thesis, all of the microarray experiments were confirmed by selecting 
key genes for quantification by real-time PCR using the SYBR® Green 
technique.  
 
In short, RNA is reversed-transcribed into cDNA. The SYBR Green dye 
binds to the double-stranded DNA, which enhances the fluorescence 
substantially, and the emission can be recorded after each cycle of 
amplification. In this thesis, the transcript level was determined by the cycle 
threshold, at which the amplification rate is switched from lagging phase to 
the exponential phase. The detected levels were normalized to the level of 
corresponding reference gene of each sample. In order to monitor the primer 
efficiencies, relative standard curves were constructed by dilution series of 
pooled cDNA representing all individual RNA samples included in the 
analysis. The obtained data were statistically analyzed by performing analysis 
of variance (ANOVA) followed by Fisher’s post-hoc analysis and expressed 
as means ± SE. 
 
 
3.3 Metabolite profiling 
 
While findings in gene expression only reflect the genotype of a system in a 
transcriptional network, knowledge of the posttranslational alterations and 
alterations in metabolite levels reveal the actual phenotype. To understand the 
complete system of a cell, it is essential to link the expression of transcripts 
and proteins with cellular metabolites. Our ability to compare the transcript 
profiles with the metabolite profiles in paper I and III, provided new 
knowledge about hepatic sex differences in metabolism. 
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There are a number of different platforms used for metabolite profiling. 
Nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry 
(MS) are the most widely used techniques for metabolite profiling although 
they differ in specificity and sensitivity. NMR can measure simultaneously all 
kinds of metabolites. However, NMR has limitations regarding sensitivity and 
should therefore only be applied to samples with high concentration of 
compounds. For enabling detection of compounds with low concentration, 
more sensitive methods should be considered such as MS. Usually, mass 
spectrometry is used to identify and quantify metabolites after separation by 
different techniques. The most established combinations of separation and 
quantification techniques are: gas chromatography/mass spectrometry 
(GC/MS), liquid chromatography/mass spectrometry (LC/MS), Fourier 
transform ion cyclotron resonance/mass spectrometry (FTICR-MS) and 
capillary electrophoresis/mass spectrometry (CE-MS) [179, 195, 196].  
 
In this thesis, 1H-NMR spectroscopy was used for metabolite profiling of 
liver perfusates (paper I), whereas CE-TOFMS was used to detect metabolites 
in liver extracts (paper III).  
 
 
3.3.1 Nuclear magnetic resonance 
 
Nuclear magnetic resonance (NMR) spectroscopy is a nondestructive, high- 
throughput technique. It has been widely employed in chemistry, 
particularly for distinguishing isomers, as well as in molecular conformation 
and in studies of molecular dynamics. Recently, NMR spectroscopy 
methods have been used to identify metabolites through the interpretation of 
NMR spin relaxation times and determination of molecular diffusion 
coefficients. When placed in a strong magnetic field, each chemically 
distinct proton within a solution exhibits a unique chemical shift that varies 
according to the extract stereochemical environment that surrounds that 
proton. The intensity of this signal depends on the concentration of the 
proton, and hence of the metabolite, in the solution. Through assignment of 
each chemical shift to a metabolite and analysis of relative changes in signal 
intensity between disease and control samples, changes in metabolite 
concentration can be monitored simultaneously for a wide range of 
metabolites. 
 
In paper I, we used 1H-NMR spectroscopy to investigate the possibility that 
low molecular weight compounds might be leaving the liver (perfusate) in a 
sex-dependent manner in healthy SD rats. 
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3.3.1.1 Reference compounds 
Reference compounds serve as internal controls for normalizing the technical 
variation between the samples. In paper I, Hexa deutero-4,4-Dimethyl-4-
silapentane-1-ammonium trifluoroacetate (DSA) was used as an internal 
control, enabling absolute concentrations of metabolites to be determined. 
 
3.3.1.2 NMR analysis 
The NMR spectroscopic measurements were made on a Bruker 600 MHz 
instrument (Bruker BioSpin, Rheinstetten, Germany) operating at 600.23 
MHz, equipped with a 5 mm inverse probe and a SampleJet sample changer. 
1H-NMR spectra were acquired using a Carr-Purcell-Meiboom-Gill 
(CPMG) spin-echo sequence to attenuate broad signals arising from 
macromolecular components [197]. 512 transients were acquired into 64 K 
data points using a spectral width of 12019 Hz with a spin echo loop time of 
76.8 ms and relaxation delay of 2.0 s with a total repetition time of 4.82 s. 
Suppression of the water resonance was achieved by presaturation during 
the relaxation delay and the spin-echo loop.  
 
3.3.1.3 Data analysis and statistics 
The time domain data were processed using a exponential window function 
with a line broadening factor of 0.3 Hz and zero-filled to yield a real 
spectrum of 64 K data points in the frequency domain after Fourier 
transformation. The spectra were manually phase corrected using Topspin 
1.3 (Bruker Biospin) and imported into Chenomx NMR Suite 5.1 (Chenomx 
Inc., Edmonton, Canada) for further analysis. Spectra were baseline 
corrected and referenced to the DSA peak [198, 199]. Metabolite signals 
were identified and quantified using the metabolite library in the software 
[200]. The 1H-NMR metabolite data with low quantification quality, 
normality could not be assumed and Friedman’s non-parametric test was 
utilized to determine effect of insulin treatment or sex. The groups were also 
compared using Student’s t-test. Differences between groups were 
considered significant at p<0.05. 
 
 
3.3.2 Capillary electrophoresis – mass spectrometry 
 
Capillary electrophoresis mass spectrometry (CE-MS) enables separation 
(CE) and quantification (MS) of low molecular-weight hydrophilic 
compounds such as amino acids and carbohydrates.  
 
Separation by CE is accomplished by electrical force applied onto the ion, 
which in turn depends on the charge and on the flow resistance. At a low 
pH, the amino groups are protonated, and protons in general are the sole 
source of charge under these conditions. The position of each peptide in a 
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CE-separation can therefore be calculated with perfect accuracy if its mass 
and the number of basic amino acids are known [201]. Its main advantages 
are the robustness, the simple separating principle with high reproducibility. 
Furthermore, CE-MS enables reproducible and comparable analysis of 
highly complex samples. 
 
In this thesis, we used CE-TOFMS to evaluate if the overlapping set of 
differentially expressed genes could be related to liver-derived intermediary 
metabolites that differentiate male and female ZDF rats regarding their 
susceptibility to develop diabetes, metabolite profiling on liver extracts was 
performed (paper III). 
 
3.3.2.1 Reference compounds 
In the paper III, L-methionine sulfone and D-camphor-10-sulfonic acid (CSA) 
were used as references for cations whereas 2-morpholinoethane-sulfonate 
(MES) served as reference for anions. 
 
3.3.2.2 Extraction  
Metabolites were extracted from liver by homogenization in methanol. The 
homogenate was mixed with Milli-Q water and chloroform (2:5) and 
centrifuged. The upper aqueous layer was centrifugally filtered through a 
Millipore 5-kDa cutoff filter to remove proteins. Finally, the filtrate was 
concentrated by centrifugation and dissolved in Milli-Q water containing 
reference compounds prior to CE-TOFMS analysis.  
 
3.3.2.3 CE-TOFMS analysis 
All CE-TOFMS experiments were performed using an Agilent CE capillary 
electrophoresis system (Agilent Technologies, Waldbronn, Germany), an 
Agilent G3250AA LC/MSD TOF system (Agilent Technologies, Palo Alto, 
CA, USA), an Agilent1100 series binary HPLC pump, and the G1603A 
Agilent CE-MS adapter- and G1607A Agilent CE-ESI-MS sprayer kit. For 
system control and data acquisition we used the G2201AA Agilent 
ChemStation software for CE and the Analyst QS for Agilent TOFMS 
software. CE-MS/MS analyses for compound identification were performed 
on a Q-Star XL Hybrid LC-MS/MS System (Applied Biosystems, Foster 
City, CA. USA) connected to an Agilent CE instrument. 
 
CE-TOFMS conditions for cationic metabolite analysis: Separations were 
carried out in a fused silica capillary (50 μm i.d. x 100 cm total length) filled 
with 1 M formic acid as the electrolyte [202]. Approximately 3 nl of sample 
solution were injected at 50 mbar for 3 s and 30kV of voltage was applied. 
The capillary temperature was maintained at 20°C and the sample tray was 
cooled below 5°C. Methanol-water (50% v/v) containing 0.5 μM reserpine 
was delivered as the sheath liquid at 10 μl/m. ESI-TOFMS was operated in 
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the positive ion mode and the capillary voltage was set at 4,000V. A flow rate 
of heated dry nitrogen gas (heater temperature 300°C) was maintained at 10 
psig. In TOFMS, the fragmentor, skimmer, and Oct RFV voltage were set at 
75V, 50V, and 125V, respectively. Automatic recalibration of each acquired 
spectrum was performed using reference masses of reference standards. The 
methanol adduct ion ([2MeOH+H]+, m/z 65.0597) and reserpine ([M+H]+, 
m/z 609.2806) provided the lock mass for exact mass measurements. Exact 
mass data were acquired at a rate of 1.5 cycles/s over a 50-1,000 m/z range 
[179]. CE-TOFMS conditions for anionic metabolite analysis: A chemically 
coated with a cationic polymer-coated COSMO (+) capillary (Nacalai Tesque, 
Kyoto, Japan) was used as the separation capillary. A 50-mM ammonium 
acetate solution (pH 8.5) was used as electrolyte solution for CE separation 
[203]. Sample solution (30 nl) was injected at 50 mbar for 30 s and -30kV of 
voltage was applied. Ammonium acetate (5 mM) in 50% methanol-water 
(v/v) containing 0.1 μM Hexakis was delivered as the sheath liquid at 10 
μl/m. ESI-TOFMS was conducted in the negative ion mode; the capillary 
voltage was set at 3,500V. For TOFMS, the fragmentor, skimmer, and Oct 
RFV voltage were set at 100V, 50V, and 200V, respectively. A flow rate of 
drying nitrogen gas (heater temperature 300 °C) was maintained at 7 L/min.  
Automatic recalibration of each acquired spectrum was performed using 
reference masses of reference standards ([13C isotopic ion of deprotonated 
acetic acid dimer (2CH3COOH-H)]-, m/z 120.03841), and ([Hexakis + 
deprotonated acetic acid (CH3COOH-H)]-, m/z 680.03554). Exact mass data 
were acquired at a rate of 1.5 spectra/s over a 50-1000 m/z range. Other 
conditions were described in a previous report [203]. 
 
3.3.2.4 Data analysis and statistics 
Processing of metabolite data includes identification of metabolites, baseline 
subtraction, dataset normalization and alignment, visualization on 2D plots 
(m/z and time) and detection of significant metabolites. 
 
In our study presented in paper III, data analysis was performed using the 
proprietary software called MasterHands (Institute for Advanced Biosciences, 
Keio University, Japan) [204, 205]. Briefly, the peaks were detected from 
sliced electropherograms (m/z 0.02 width), and accurate m/z values were 
calculated by Gaussian curve fitting. The migration times of the detected 
peaks were next normalized by a time-warping function, whose numerical 
parameters were optimized by a simplex method with peak matching across 
multiple data sets based on dynamic programming techniques [206]. Any 
redundant features, such as isotopic peaks, fragments and adduct ions, were 
removed. Finally, the metabolites contained in the standard compounds were 
assigned to the remaining features by matching their m/z values and 
normalized migration times.  
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All data were subjected to analysis of variance (2-way ANOVA) followed 
by Fisher´s post hoc analysis and expressed as mean ± SE. Differences 
between groups were considered significant at p<0.05. 
 
 
3.4 In situ liver perfusion 
 
For analysing the amount of glucose produced by male and female livers, 
respectively, we performed in situ liver perfusion. This technique enables 
collection of metabolites that are produced by an intact organ such as the 
liver, in a living system. In paper I, we present data showing measurements 
of hepatic glucose output (HGO) and other identified metabolites detected in 
the perfusates using 1H-NMR spectroscopy. 
 
In short, the rats are anaesthetized and the intact liver is exposed. Non-
circulating Krebs-Henseleit bicarbonate buffer is entered via the portal vein, 
as described previously [207]. For the aim of our studies, no gluconeogenic 
precursors should be present in the buffer and the perfusion pressure and 
flow rate kept constant. Samples are finally collected from the inferior caval 
vein, starting five min after perfusion initiation when the liver appears to be 
cleared from any remnants such as blood. In our study, hepatic glucose 
output was calculated using the mean glucose concentration in relation to 
flow rate and hepatic dry weight.  
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4 RESULTS 
 
The results from the papers included in the thesis are summarized here, and 
described in more detail below: 
 
A. Sex differences in hepatic fuel metabolism were characterized in 
healthy male and female rats. Male rats showed higher ratios of 
insulin to glucagon levels, higher levels of hepatic glycogen, lower 
degree of hepatic AMPK phosphorylation, higher expression of 
hepatic gluconeogenic genes and higher hepatic glucose output, as 
compared to the females. 
 
B. Differences in effects of short-term high-fat feeding (SOD and CBD) 
were demonstrated on hepatic insulin sensitivity, gene expression, 
lipid metabolism and plasma lipids. Cocoa butter did not affect 
plasma total TG levels, VLDL-TG or hepatic insulin sensitivity. 
Safflower oil increased hepatic β-oxidation, was beneficial in terms 
of circulating VLDL-TG, but led to reduced hepatic insulin 
sensitivity. CBD showed effects on hepatic gene expression that 
might lead to increased lipid synthesis, lipotoxicity, inflammation 
and IR if the diet would be extended. 
 
C. Sex differences in the development of hepatic IR were investigated 
using male and female ZDF rats as a model. Changes in hepatic gene 
expression revealed reduced hepatic lipogenesis, increased FA 
oxidation and metabolic stress in the high-fat diet fed females and 
diabetic male rats, compared to the healthy females. 
 
D. Sex differences in hepatic metabolic control were translated and 
extended into sex-different hepatic metabolites. Metabolite profiles 
of hepatic perfusates from healthy rats using NMR verified that male 
livers contained more glucose than female perfusates. Liver-derived 
lactate was also higher in males, and there was a trend towards 
higher levels of glycerol and the glucogenic amino acids glutamine 
and glutamate in males.  
 
E. Testosterone treatment in male diabetic ZDF rats reduced the hepatic 
fat content. Also, the treatment increased blood glucose levels, 
reduced glucose tolerance and increased circulating levels of TG-rich 
VLDL particles. Surprisingly, testosterone reduced STAT3 activity, a 
key mediator of leptin, essential for hepatic insulin sensitivity. 
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4.1 Sex-different hepatic glycogen content and glucose output 
in rats (Paper I) 
 
To investigate underlying molecular mechanisms of possible sex-specific 
development of hepatic IR, we decided to first improve the knowledge of how 
healthy male and female rats differ regarding hepatic fuel (lipid and 
carbohydrate) metabolism. In paper I, we concluded that males had higher 
ratios of insulin to glucagon levels, higher levels of glycogen, lower degree of 
AMPK phosphorylation, higher expression of gluconeogenic genes and 
higher hepatic glucose output. Possibly, these sex differences reflect a higher 
ability for the healthy male rat liver to respond to increased energy demands. 
 
Out of 27 649 gene probes represented on the microarrays, approximately 3 
500 were detected in liver. Among these, 383 (11%) transcripts were 
expressed significantly higher in females whereas 399 (11%) transcripts were 
significantly higher in males (cut-off: 5% FDR and 1.5 fold change). In line 
with previous reports from our lab [107], the female-predominant genes are 
involved in hepatic uptake of long-chain fatty acids, synthesis of TG and 
assembly of VLDL particles. In addition, a male-predominant capacity for 
mitochondrial and peroxisomal FA oxidation was revealed. Also, the male 
rats had higher levels of gene products for glucose uptake and synthesis of 
glycogen compared to the females.  
 
The normal metabolic state of an individual can be affected by different 
stressors such as fasting. To investigate how the metabolism of healthy male 
and female rats respond to this type of stress, they were fasted for either 4h 
(absorptive state) or 12h (post-absorptive state) and compared regarding 
hepatic gene expression. Interestingly, most gene products showed a greater 
sex-difference in the post-absorptive state, including higher levels of ACOX1, 
CPT-1a, GOT1, G6Pase and SCD1 in males.   
 
Hepatic TG content, FA oxidation rate and ketone bodies in the blood of the 
fasted animals was determined in order to study the relation to the hepatic 
mRNA expression levels. However, no sex differences could be detected at 
these levels. The hepatic glycogen stores were measured in the animals 
showing that the males had higher levels of hepatic glycogen as compared to 
females.  
 
Hepatic glucose output (HGO) was determined by in situ perfusion of the 
livers. Interestingly, glucose levels were higher in perfusates collected from 
male rats (P<0.0001), but there were no significant differences in HGO 
between 4 and 12h fasting. When blood glucose levels were determined at 
different durations of fasting, a significant decrease was observed after 12h 
but sex differences could not be detected at any time point. The discrepancy 
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between glucose levels in blood and liver perfusates might be explained by 
differences in glucose uptake by peripheral tissues. 
 
To explore the possibility that other low molecular weight compounds might 
be leaving the liver in a sex-dependent manner, the perfusates were also 
analysed using 1H-NMR spectroscopy. Quantitative analysis verified that 
perfusates generated from male livers contained more glucose, as compared 
to females (P<0.01). There were also significantly higher levels of lactate 
detected in male samples (P<0.01). 
 
To test whether male and female livers respond equally well to insulin at the 
level of insulin receptor signaling, the responses to insulin were compared 
between male and female rats regarding Akt-phosphorylation (Ser473) and 
gene expression. No sex-difference could be observed in the degree of Akt-
phosphorylation 40 min after insulin treatment, using an ELISA assay. The 
effect on blood glucose levels was the same in males (reduced from 6.1+0.3 
to 2.5+0.3) and females (reduced from 5.8+0.4 to 2.3+0.4) 40 min after 
insulin treatment. 
 
 
4.2 Cocoa butter and safflower oil elicit different effects on 
hepatic gene expression and lipid metabolism in rats (Paper 
II) 
 
In paper II, we compared the effects of cocoa butter-enriched diet and 
safflower oil-enriched diet on hepatic gene expression, lipid metabolism, 
insulin sensitivity and plasma lipid profiles, in healthy male rats.  
 
Cocoa butter-enriched high-fat feeding for 3 days increased hepatic 
triglyceride (TG) content and fatty acid (FA) oxidation rate to similar 
extents (60% and 70% respectively). No effects were observed on plasma 
total TG levels or TG-rich VLDL particles. In the safflower oil-fed animals, 
hepatic TG was increased to the same extent (60%) but FA oxidation 
enhanced to a greater extent (170%), as compared to the cocoa butter group. 
Plasma total TG and VLDL-TG were lowered in the oil-fed rats.  
 
Using whole-genome rat oligo microarrays hepatic transcript profiles were 
generated reflecting lipid-mediated gene activities. Cocoa butter had a 
greater impact on gene expression than safflower oil, and most effects were 
dependent on the type of lipid. Rats fed cocoa butter diet had increased 
levels of several gene products from important biosynthetic pathways such 
as cholesterol and bile acid synthesis. Gene products involved in stress-
mediated survival pathways within the liver seemed to be increased to 
similar extents by the two high-fat diets, although the effect on IGFBP-1 
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protein was higher with cocoa butter. SCD-1 and -2 were among the gene 
products being repressed by high-fat feeding, with safflower oil eliciting the 
greatest effect.  
 
Only safflower oil-based high-fat feeding had a negative effect on hepatic 
insulin sensitivity, using the ratio between phosphorylated Akt and total Akt 
as a measure of insulin signalling capacity. These findings suggest that the 
two different types of fat used in this study, will affect hepatic gene 
expression, sterol metabolism, and insulin sensitivity differently. 
 
 
4.3 Sex-dependent hepatic transcripts and metabolites in the 
development of glucose intolerance and insulin resistance 
in Zucker diabetic fatty rats (Paper III) 
 
With the data concluded from the previous studies, in paper III we wanted to 
investigate if differences in liver functions could provide clues to why male 
Zucker diabetic fatty rats (mZDF) spontaneously develop hyperlipidemia, 
hyperglycemia and diabetes, whereas females (fZDF) only become diabetic 
when fed a diabetogenic high-fat diet (HF-fZDF).  
 
By using whole-genome arrays, we first identified high-fat diet-induced 
changes in hepatic gene expression, comparing the non-diabetic females with 
the diabetic females (13-week-old fZDF and HF-fZDF). Out of 27 649 gene 
probes printed on the arrays, 94 were differentially expressed between the 
groups (using a 5% FDR and a cut-off at 1.5-fold difference). Functional 
annotation of the differentiated transcripts revealed that females developing 
IR and glucose intolerance have increased levels of gene products for FA 
oxidation (e.g. CPT-1a) and reduced levels of transcripts for lipid synthesis 
(e.g. ACC). Signs of increased oxidative stress included elevated mRNA 
levels of metallothionein (Mt1) and reduced levels of glutathione S-
transferases (GST). 
 
To find sex-dependent hepatic gene products that might be related to disease 
development, transcript profiling was performed comparing the non-diabetic 
female with the diabetic male rats (13-week-old fZDF and mZDF). This 
resulted in 168 differentially expressed hepatic transcripts, being either male- 
or female-predominant. Interestingly, among 94 fat-induced changes, 32 were 
sex-dependent. Overlapping differences (comparing the two sets of arrays) 
included several gene products for FA oxidation (male-predominant and 
induced by high-fat diet) and lipid synthesis (female-predominant and 
reduced by high-fat diet). Also, signs of increased oxidative stress, including 
elevated mRNA levels of Mt1 and reduced levels of GST were observed. 
Ten gene products with differential expression and important functions in 
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hepatic lipid metabolism or metabolic stress responses were confirmed 
through real time quantitative PCR. 
 
To evaluate if the overlapping differentially expressed genes could be related 
to liver-derived intermediary metabolites, metabolite profiling on liver 
extracts were performed using a method based on capillary electrophoresis 
time-of-flight mass spectrometry (CE-TOFMS). Among 151 low molecular 
weight compounds (LMC) detected in liver extracts, 45 were found to be 
significantly different between HF-fZDF and fZDF, whereas 34 were 
different between mZDF and fZDF. In line with the findings in the transcript 
profiles, the observed metabolic changes indicate increased activity through 
catabolic pathways (FA oxidation and amino acid degradation) and reduced 
biosynthesis of GSH and its precursors within the livers of HF-fZDF. 
 
These liver-derived molecular profiles indicated that males and females might 
respond differently to increased hepatic lipid infiltration. The effects of three 
days high-fat feeding on the expression of ten selected genes for lipid 
turnover and metabolic stress responses were investigated in healthy male and 
female Sprague Dawley (SD) rats. This short-term high-fat feeding has 
previously been reported to trigger a gene expression program for hepatic 
lipid disposal and cell survival in SD rats [208]. Of the investigated 
transcripts, NAD(P)H:quinone oxidoreductase 1 (NQO1) was significantly 
altered in response to high-fat feeding but only in the males. In contrast, 
Mt1 seemed to be more diet-induced in females, increasing the sex-different 
expression of this gene. 
 
 
4.4 Testosterone–mediated effects on the liver differ between 
lean and obese Zucker rats (Paper IV) 
 
In the fourth paper, we wanted to investigate the effects of testosterone 
treatment and further explore a role of testosterone on hepatic metabolism in 
male ZDF (fa/fa), using lean Zucker (fa/+) (ZLC) rats as a control. The use of 
testosterone as a possible treatment has been suggested for hypogonadal 
males with T2D and metabolic syndrome [209].  
 
Three weeks of testosterone treatment significantly increased blood glucose 
and VLDL-TG levels in the obese ZDF rats and significantly reduced the 
glucose tolerance. Also, ZDF-specific effects were observed on hepatic lipid 
metabolism, with decreased hepatic TG content in response to testosterone. 
 
To identify testosterone-regulated hepatic genes, and to compare the effects 
of testosterone in ZLC and ZDF rats, whole-genome rat oligo microarrays 
were used. 827 transcripts were altered in response to testosterone in lean, 
Carolina Gustavsson 
 
36 
 
and 412 were regulated in obese. Among those, only 64 transcripts were 
testosterone-regulated in both lean and obese, whereas 330 transcripts were 
differently regulated between the groups. Testosterone treatment in both 
lean and obese rats reduced the expression of genes for de novo lipid 
synthesis (IRE-BP1, ChREBP, SREBP1c, FAS, ACC1, Elovl6 and 
Adiponutrin), although the effects were more pronounced in the obese. 
Stimulatory effects of testosterone were more prominent in the lean rats, 
including IRS2, PEPCK and Angptl4. The obese state was associated with 
increased levels of IRS1, IRE-BP1, CPT-1a, SHP and FGF21, regardless of 
testosterone status. Lower rates of lipid synthesis together with enhanced 
capacity for fatty acid oxidation (CPT-1a) and bile acid synthesis (CYP7A1) 
might explain the lowering effect on hepatic TG observed in T-ZDF.  
 
We also noted that hepatic STAT3 phosphorylation was reduced by 
testosterone in both groups. Interestingly, this effect on STAT3 could also 
be seen in cultured human hepatocytes, in the presence or absence of leptin.  
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5 DISCUSSION 
 
 
5.1 Sex differences in lipid and carbohydrate metabolism in rat 
liver 
 
5.1.1 Carbohydrate metabolism 
 
Gene expression 
In paper I, we confirmed previous observations showing a male-predominate 
turn-over in hepatic carbohydrate metabolism [107] by performing microarray 
analysis. Higher levels of gene products for glucose uptake and synthesis of 
glycogen were observed in the healthy male rat livers compared to the 
females. Interestingly, these sex differences seemed to be enhanced upon 
prolonged fasting (post absorptive state, 12h fasting) in the mRNA expression 
of e.g. glutamate oxaloacetate transaminase 1 (GOT1) and the gluconeogenic 
enzymes PEPCK and G6Pase. For this reason, it could be speculated that the 
male are more efficient in producing glucose and glycogen.  
 
In paper III, the impact of short-term high-fat diet (safflower oil) on 
carbohydrate turn-over was tested using PEPCK as a marker. The diet 
decreased the mRNA expression of PEPCK in both sexes. However, no 
significantly difference was observed by comparing the males and the females 
but there was a clear trend of a male-predominate expression, indicating that 
the males are more vulnerable to an increased lipid load/accumulation, 
resulting in increased hepatic glucose production/output.  
 
In paper III, we wanted to expand our knowledge on hepatic sex differences 
in relations to IR and used the ZDF rat as a model for the study of disease 
development. We determined transcript profiles and classified the significant 
different gene products by their function. In line with the previous studies, 
PEPCK was confirmed to be significantly elevated in the diseased males 
(mZDF), no difference between the female groups were observed.  
 
Hepatic glucose output and glycogen content 
The hypothesis that healthy male rat livers produce more glucose compared to 
female was tested in paper I. Hepatic glucose output (HGO) was determined 
by in situ perfusion of the livers. Interestingly, glucose levels were higher in 
perfusates collected from male rats supporting our findings at the gene 
expression level. A sex-difference in hepatic glucose output has as far as we 
know not been described before, but there are reports on male-predominant 
hepatic glycogen content, G6Pase [210] and PEPCK activities [211]. In line 
with this, in paper I we could report a higher level of hepatic glycogen in the 
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male rats compared to the females. For future studies, it would be of interest 
to determine the HGO and glycogen content in the livers of the different 
groups of ZDF rats in order to investigate if these sex differences also may be 
a contributing factor the development of T2D in these rats.  
 
PEPCK activity has been shown to be reduced by castration or estrogen 
treatment. Estrogens have also been shown to decrease the expression of 
PEPCK in virgin female rats [212] as well as G6Pase protein levels and 
enzyme activity in ob/ob mice [213]. Thus, estrogens have been suggested as 
an anti-hyperglycemic agent in this model of T2D. Accordingly, estrogen 
receptor α deficient (ERαKO) mice develop fatty liver, have higher fasting 
blood glucose, plasma insulin levels and impaired glucose tolerance [80]. 
Since estrogen levels are higher in fertile females than males, estrogen 
signaling seems to be essential for these hepatic sex differences. However, 
other sex-dependent hormones such as testosterone and growth hormone 
(GH) are likely to be of similar importance. As demonstrated in paper IV, 
testosterone treatment in the lean ZDF rats (but not the obese) induced the 
hepatic gene expression of PEPCK. This may indicate that testosterone 
stimulate glucose turnover through enhanced hepatic insulin sensitivity (IRS2 
and Angptl4), leading to improved regulation of hepatic glucose and VLDL 
output in the lean rats. 
 
Another interesting sex-difference was observed regarding plasma levels of 
insulin and glucagon in the healthy SD rats. The male rats had higher ratios 
of plasma insulin to glucagon levels, which might also contribute to higher 
glycogen content in males. In spite of this sex-difference in insulin to 
glucagon ratios, blood glucose concentrations were the same in male and 
female rats, which might be interpreted as male rats being less sensitive to 
insulin. It should also be noted that AMPK was Thr172-phosphorylated to 
lower degrees in male livers, indicative of higher activity through 
glucogenic pathways as compared to females. Whether a cause-effect 
relationship between higher insulin to glucagon ratios, greater capacity for 
glycogen synthesis and less AMPK activity exists in male rat livers, and 
whether this explains the greater HGO in male rat livers observed in this 
study, have to await further investigations. 
 
There is an established link between gluconeogenesis and glycogen synthesis, 
meaning that a higher rate of glucose production from e.g. amino acids, 
lactate or glycerol will also lead to a greater capacity to synthesize glycogen. 
A similar pattern of mRNA expression was observed for the gluconeogenic 
enzymes GOT1, G6Pase and PEPCK, suggesting a common mechanism of 
regulation. Further experiments are required to determine whether this 
explains the male-predominant content of glycogen.  
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A sex-difference in hepatic glucose output has to our knowledge, not been 
reported before. Since men are more prone to use carbohydrates as energy 
source in a fasted state, it is logical that they have higher levels of HGO. 
Increased supply of substrates is necessary for increased HGO and an increase 
in gluconeogenesis is crucial for higher rates of HGO. However, in patients 
with decreased peripheral insulin sensitivity, this increased HGO in men may 
lead to hyperglycemia and exhaust the system, eventually impair the 
pancreatic β-cell function.  
 
 
5.1.2 Lipid metabolism 
 
Gene expression 
In paper I, we accentuated previous observations showing a female-
predominate turn-over in hepatic lipid mRNA expression [107]. As expected, 
higher levels of gene products for lipid uptake, lipid output and synthesis of 
lipids (TG and VLDL particles) were observed in the healthy female rat livers 
compared to the males. However, transcripts involved in lipid turn over and 
FA oxidation were more prominent in the male rat livers. As for the observed 
sex differences in the carbohydrate metabolism, these effects were enhanced 
after 12h fasting. As described in previous studies [107, 214], CD36 (fatty 
acid translocase) has been implicated as an important player in the context of 
hepatic lipid uptake and is female-predominant. CD36 is increased during 
situations of increased hepatic lipid content [107, 215] but reduced during 
starvation [214], indicating that it might be involved in anabolic actions. 
Whereas for the hepatic FA oxidation, acyl-coenzyme A oxidase 1 (ACOX1) 
and CPT-1a showed higher levels of mRNA expression in the males. These 
results were in line with the increased expression levels of genes for FA-
oxidation in HF-fZDF and mZDF, as compared to fZDF (paper III). 
 
In paper III, the impact of short-term high-fat diet (safflower oil) on lipid 
turn-over and FA oxidation were investigated using ACCα and CPT1-a as 
markers. As expected, the mRNA expression of ACCα was significantly 
higher in the livers of the female rats. However, the expression of CPT-1a 
was not shown to be significantly different comparing the males and the 
females but there was a clear trend of a male-predominate expression, in line 
with previous results. In line with this, female rats have previously been 
shown to have higher rates of hepatic FA uptake [53, 216], esterification 
[53], VLDL-TG formation and output [55] as compared to males. During 
situations of increased adipose lipolysis (e.g. fasting) and availability of 
NEFA in the blood stream, the liver will take up more NEFA which will 
lead to the activation of PPARα and thereby increased expression of gene 
products for FA oxidation [217] and ketogenesis [218]. Male rats have been 
shown to have higher levels of hepatic PPARα [219] and to be more 
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responsive to peroxisome proliferators than female rats [220, 221], 
including higher rates of FA oxidation. Our finding that fasting induced the 
PPARα-dependent genes ACOX and CPT-1a in males to a greater extent 
than in females might thus be explained by higher levels of PPARα in male 
liver. Testosterone treatment in the lean and obese ZDF rats reduced the 
expression of several key genes for de novo lipid synthesis (IRE-BP1, 
CHREBP, SREBP1c, FAS, ACC1, Elovl6 and Adiponutrin), although the 
effects were more pronounced in the obese (paper IV). This indicate that 
testosterone have a greater effect on de novo lipid synthesis in the obese ZDF. 
The latter might be a consequence of higher SHP mRNA levels in the obese 
state, since SHP has been shown to down-regulate expression of CHREBP 
and SREBP1c.  
 
FA oxidation and TG content 
In contrast to the observed differences at the transcript levels, we did not 
detect any sex-difference in the amount of hepatic TG content in the healthy 
SD rats (paper I). This might be explained by a compensational mechanism in 
the females with greater capacity for TG synthesis by having a greater VLDL-
TG output compared to the males, as described in previous studies [55]. Also, 
reduction of genes encoding leptin have been reported in estrogen-treated 
obese female mice [83]. Thus, it might be speculated that leptin is involved in 
promoting TG output. 
 
 
5.2 Effects of short-term high-fat feeding on hepatic insulin 
resistance in male rats 
 
Short term high-fat feeding to rats using safflower oil as lipid source, has 
shown to result specifically in hepatic fat accumulation and has been used as 
a model to study the mechanisms underlying hepatic IR [222]. In contrast, 
studies based on cocoa butter as lipid source with the saturated fatty acid 
stearic acid as the main FA, have shown to  have a neutral effect on the 
plasma lipid profiles [223]. Ingested cocoa has also been shown to reduce de 
novo lipid synthesis in rat liver [224]. In paper II, we investigated the effects 
of short-term (three days) high-fat feeding on the hepatic metabolism in male 
rats. The effects of two different types of diets were compared and in relation 
to a control standard diet (StD) (9% fat). The safflower oil-enriched diet 
(SOD) (52% fat) increased hepatic β-oxidation, was beneficial in terms of 
circulating VLDL-TG particles, but led to reduced hepatic insulin signaling. 
Whereas the cocoa butter-enriched diet (CBD) (52% fat) was neutral 
regarding serum lipids and hepatic insulin sensitivity. The effect of cocoa-
butter was more extensive at the level of hepatic gene expression compared 
to the effects of safflower oil. The observation in the SOD rats showing an 
increase in hepatic β-oxidation but reduced hepatic insulin sensitivity can be 
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compared to the results in paper III where the diabetic mZDF rats showed a 
similar pattern. Increased FA oxidation rates are known to increase the 
hepatocellular levels of ROS and the risk of developing hepatic IR [170] 
thus, confirm our findings. 
 
Hepatic lipid content 
It is well established that fat accumulation in the liver leads to IR [225]. 
However, it is not clear how long time of fat accumulation it will take in 
order for those effects to be detected. In paper II, after only three days of 
HFD the level of TG was increased in the livers of the fat fed animals 
compared to the controls but no differences between the diets were 
identified. However, only the SOD fed rats showed elevated levels of 
hepatic cholesterol suggesting lipid-specific effects on hepatic lipid 
metabolism.  
 
Plasma lipid profiles 
The lipid-specific effects were also analyzed in plasma. Safflower oil 
decreased VLDL-TG particles and increased cholesterol-rich VLDL 
particles. At the same time, HDL cholesterol was reduced. No difference 
was observed between the male rats fed CBD and StD. The diet-specific 
effects on plasma lipids are in agreement with previous studies [226], and 
might partly be explained by differences in hepatic FA oxidation rates. The 
level of TG in plasma is most often related to VLDL production in the liver, 
and this in turn is dependent on whether FA are being used for FA oxidation 
or re-esterification [227]. The enhanced FA oxidation rate in the SOD-fed 
rats indicate that both de novo FA synthesis [228] and lipoprotein formation 
was reduced [229], leading to lowered levels of plasma TG. In comparison, 
female rat fed a SOD demonstrated even lower levels of VLDL-TG 
compared to the males (unpublished data). Additional studies are needed to 
further speculate about this sex-difference. 
 
Hepatic gene expression profiles 
SOD mediated an increase in the expression of important gene products 
involved in bile acid production and cholesterol excretion, CYP7A1 and 
ABCG5. The SOD-mediated increase in hepatic cholesterol might lead to 
liver X receptor (LXR) stimulation and thus explain the increased 
expression of CYP7A1 [230] and the sterol transporter ABCG5 [231]. This 
effect of safflower oil on gene products involved in hepatic cholesterol 
turnover has to our knowledge not been described before but might be 
related to the reduced expression of SCD-1 and capacity to export CE in 
VLDL particles in the SOD-fed rats. Common effects of the two diets on 
gene expression included increased levels of p8, DIG-1, IGFBP-1 and 
FGF21, as well as reduced levels of SCD-1 and SCD-2. This indicates that a 
lipid-dependent program for hepatic lipid disposal and cell survival was 
                                                     Sex-different control of hepatic metabolism  
 
43 
 
induced, independently of the lipid source. The observation that cocoa butter 
exerted a similar degree of SCD-1 reduction as did safflower oil has to our 
knowledge not been described before. The mechanism behind this effect is 
as yet unknown, but data presented herein suggest that it is independent of 
reduced SREBP-1 maturation [232]. It has been suggested that inhibition of 
SCD-1 in the liver results in secretion of VLDL particles that are highly 
enriched in SFA-rich CE, giving rise to SFA-CE-rich LDL particles. 
Increased delivery of SFA to macrophages leads to accumulation of SFA, 
enhanced inflammatory cytokine secretion and a proinflammatory 
phenotype. In the present study, reduced expression of SCD-1, was in 
parallel with increased hepatic cholesterol, increased VLDL cholesterol and 
reduced HDL-cholesterol. Whether this effect would persist upon longer 
periods of high dietary intake of safflower oil is not known and should be 
addressed. The high-fat diet-mediated increase in FGF21 mRNA is 
interesting, since FGF21 has been shown to increase β-oxidation. FGF21, a 
hormone induced by fasting, is predominantly expressed in the liver and has 
beneficial effects on glucose homeostasis and insulin sensitivity both in 
rodents [233] and humans [234]. It has also been shown that FGF21 induces 
SOCS2, blocks GH-dependent STAT5b signaling and alters the expression 
of GH-regulated genes during starvation [235]. Among other GH-
suppressed gene products [236], hepatic IGFBP-1 expression was found to 
be induced by FGF21 [235]. Our finding that FGF21 was induced by high-
fat feeding in parallel with increased IGFBP-1 and increased FA oxidation 
is in line with the reports cited above, and adds to the picture of FGF21 as a 
sensor of FA availability, during starvation as well as during hepatic fatty 
infiltration. 
 
Hepatic insulin sensitivity 
Only a few studies have been reported reduced insulin sensitivity after only 
a short period of time of high-fat feeding. In paper II, we reported that male 
rats fed SOD for only three days had reduced hepatic insulin-mediated 
phosphorylation of Akt and GSK3β. These findings were in line with a 
previous report [222] in which blunted insulin-mediated suppression of 
hepatic glucose output (HGO) also was reported. HGO was not investigated 
in paper II but would be of interest for future investigations as well as other 
signaling molecules up-stream of Akt (e.g. IRS1 and IRS2). Interestingly, 
these effects on Akt phosphorylation was not detected in the rats fed CBD 
for three days. However, it cannot be ruled out that cocoa butter feeding 
would lead to the same detrimental effect if the diet would be prolonged.  
Interestingly, unpublished data from our group show that SOD does not 
affect the hepatic insulin-mediated activation of Akt in female rats. 
 
 
Carolina Gustavsson 
 
44 
 
5.3 Sex differences in the development of hepatic insulin 
resistance 
 
It is well accepted that men are more prone to develop metabolic syndromes 
including IR and T2D than premenopausal women [6, 7, 237]. This 
observation can be linked to differences in body composition and sex 
hormones. However, the underlying molecular mechanisms are not entirely 
explained. One aspect of hormone-dependent differences between males and 
females comprise liver functions. Animal studies support a protective role of 
estrogen-mediated effects on the liver since both male and female ERαKO 
mice develop non-alcoholic fatty liver disease (NAFLD), hepatic IR and 
impaired glucose tolerance [80]. In this thesis, we used male and female 
Zucker diabetic fatty rats to further investigate possible mechanisms that 
may be involved in the sex-specific development of hepatic IR.  In parallel, 
we studied sex differences in the livers of healthy Sprague-Dawley rats. 
 
Blood glucose and insulin levels 
As expected, the blood glucose and insulin levels increased with time in the 
mZDF rats, confirming the disease development in these animals thus, 
confirming the notion that fZDF rats are less susceptible to diabetes 
development [187, 238]. However, four weeks of high-fat (48% kcal fat) 
feeding will induce the development of marked hyperglycemia in fZDF, 
which leads to islet dysfunction and diabetes within the following four 
months [238]. Elevated levels of insulin indicate that the β-cells are still 
functioning, trying to repress the elevated blood glucose levels in these 
animals. With time, it is expected that the insulin production will shut down 
due to exhaustion of the system, as part of the consequences of T2D. 
 
Hepatic fuel metabolism 
As discussed earlier, at the transcriptional level, the most prominent sex 
differences in the disease development in the ZDF rats included FA oxidation 
(male-predominant) and lipid synthesis (female-predominant). This is in line 
with previous studies [107] as well as our own observations in the healthy SD 
rats (paper I).  
 
Adiponutrin (Pnpla3) showed the greatest sex-difference among the gene 
products being confirmed to be female-predominant and reduced by high-fat 
feeding in paper III. In line with this, we observed a reduction of 
adiponutrin after testosterone treatment in the mZDF, described in paper IV. 
Adiponutrin is a predominantly liver-expressed transmembrane protein with 
phospholipase activity that is regulated by fasting and feeding. Although its 
putative role in metabolic disease development has only recently started to 
be explored, various genome-wide association studies have identified the 
adiponutrin gene to be associated with liver-related phenotypes [239-241]. 
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Since it is up-regulated in response to feeding and down-regulated in the 
fasted state, a potential role for adiponutrin in lipid storage has been 
suggested [242-244]. Interestingly, genes of importance for de novo lipid 
synthesis (such as ACCα) were found to be co-regulated with adiponutrin in 
our studies. This finding is supported by reports showing an increased 
expression of the adiponutrin gene by the transcription factors SREBPs, 
PPARγ and ChREBP [242, 245].  
 
Previous findings have shown a female-predominant efficiency of 
incorporation of hepatic FA into TG and VLDL particles and secretion of 
TG-enriched lipoprotein particles. Thus, this ability may also contribute to a 
reduced hepatocellular load of lipids in obese females (fZDF). Elevated 
levels of hepatic FA in the HF-fZDF and mZDF might be caused by 
saturation in this lipid-clearing system. This might in turn activate PPARα-
dependent genes and hepatic FA oxidation, as well as reduce the actions 
through SREBP-dependent lipogenic pathways. Results obtained in paper 
III are in line with this and could be exemplified by higher expression levels 
of genes for FA-oxidation (such as CPT-1a) in HF-fZDF and mZDF, as 
compared to fZDF.  
 
Interestingly, higher FA oxidation rates are known to increase the 
hepatocellular levels of ROS and the risk of developing hepatic IR [170]. 
We did not determine hepatic insulin sensitivity in. However, the expression 
of the insulin-induced gene 1 (Insig-1), a negative regulator of SREBP-
maturation and lipogenesis [246], was significantly lower in the HF-fZDF 
and mZDF as compared to the fZDF. Interestingly, overexpression of 
hepatic Insig-1 or -2 has previously been shown to reduce lipogenesis in 
obese male ZDF rats [247]. 
 
Hepatic oxidative stress 
By comparing the transcript profiles of the HF-fZDF and mZDF, it was 
indicated that the production of reactive oxygen spices (ROS) were increased 
compared to the fZDF (paper III). These observations included increased 
levels of metallothionein and angiotensinogen mRNA, both known to be 
induced by various forms of oxidative stress. Surprisingly, two GST 
isoenzymes (GSTa1 and GSTm2) as well as quinine oxidoreductase 1 
(NQO1) were reduced in the insulin resistant rats (HF-fZD and/or mZDF). 
The reason for this is not known, but is likely to reduce the hepatic 
detoxification capacity. Metallothioneins are potent cellular antioxidants 
that play important roles in essential trace element homeostasis, metal 
detoxification, and in the protection against various injuries resulting from 
ROS [248], including the development of diabetes and its complications. 
Previous studies in fatty livers of obese ZDF rats have shown increased 
levels of malondialdehyde (a lipid peroxidation product) [249] and reduced 
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levels of GSH [250, 251], supporting the idea of increased hepatic ROS 
production and GSH consumption in this model.  
 
 
5.4 Sex differences in hepatic metabolites 
 
Hepatic perfusates of healthy SD rats 
As discussed earlier, we concluded that healthy male rats have higher levels 
of hepatic glucose output compared to the females (paper I). This difference 
was detected in collected perfusates produced from in situ liver perfusion. 
With the use of 1H-NMR spectroscopy analysis of the perfusates, we 
extended our search for metabolites produced by the liver of the 12h-fasted 
male and female rats. Using this approach, we identified glucose, lactate, 
glycerol, propionate, several amino acids and ketone bodies as being 
released from the liver. Further, quantitative analysis of the perfusates 
verified that male livers contained more glucose than females. Liver-derived 
lactate was also higher in males, and there was a trend towards higher levels 
of glycerol and the glucogenic amino acids glutamine and glutamate in 
males. These findings are in line with our previous observations of the 
mRNA expression of the key gluconeogenic enzymes, indicating that the 
male liver is more active in producing and exporting not only glucose but 
also metabolites important for glucose production. 1H-NMR spectroscopy 
analysis on rat liver perfusates has to our knowledge not been performed 
before. With the use of this technique, we are able to support previous 
findings but also further contribute to the understanding of the complete 
system, thus sex differences in the healthy rat liver.  
 
Hepatic extracts from ZDF rats 
Overlapping differences in the transcript profiles included several gene 
products for FA oxidation (male-predominant) and lipid synthesis (female-
predominant) as well as oxidative stress (paper III). To evaluate if these 
differentially expressed genes could be related to liver derived metabolites 
that differentiate male and female ZDF rats regarding their susceptibility to 
develop diabetes, metabolite profiling on liver lysates and plasma was 
performed by using CE-TOFMS. This method enables separation and 
quantification of low molecular weight hydrophilic compounds such as 
amino acids and carbohydrates [203]. The most differential pathway 
detected from the CE-TOFMS analysis involved metabolites related to 
Glutathione (GSH), an important antioxidant involved in the response to 
oxidative stress. The cell is constantly balancing between GSH (red) and the 
oxidative (ox) form of Glutathione (GSSG). Normally, GSH is the 
predominant form and exists in most liver cells, the GSSG content is less 
than 1% of GSH [252]. An imbalance may cause an increase in the levels of 
oxidative stress [253, 254]. Livers from HF-fZDF had significantly lower 
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levels of GSH as compared to fZDF, indicating a greater usage of GSH due 
to increased oxidative stress. Although mZDF and fZDF rats had almost 
similar GSH levels, many glutathione related metabolites or substrates 
(ophthalmate, 2-aminobutyrate, glycine, hypotaurine and serine) were lower 
in mZDF (as compared to fZDF). These results indicate that the capacity of 
GSH production was lower in male rats, and that GSH turnover was higher 
in females. Interestingly, major differences in ophthalmate levels were 
observed, higher levels in HF-fZDF, whereas mZDF had lower levels (as 
compared to fZDF). Ophthalmate (γ-Glu-2-aminobutyrate-Gly) has 
previously been shown to be synthesized through the same pathway as GSH 
[179]. The synthesis of Ophthalmate is produced from 2-aminobutyrate 
through γ- glutamylcysteine synthetase (GCS) and glutathione synthetase. 
GCS is the rate- limiting enzyme and feedback-inhibited by GSH, and thus 
GSH consumption leads to GCS activation, resulting in enhanced 
biosynthesis of ophthalmate. Since ophthalmate levels were shown to 
predict of the amount of GSH production [179], ophthalmate measurements 
provide valuable information about hepatic GSH turnover. Reduced levels 
of GSH in HF-fZDF, while both ophthalmate and its substrate 2-
aminobutyrate were increased, indicate that although high-fat feeding in 
fZDF rats generates oxidative stress, the capacity to synthesize GSH might 
still be high due to sufficient amount of substrates (Cys, Glu, Gly, Ser etc). 
The substrates in GSH synthesis may be directly or metabolically provided 
from the high-fat diet, since GSH can be regenerated from GSSG using 
NADPH produced in the pentose phosphate pathway. These results indicate 
that the capacity of GSH production was higher in female rats, which at 
least partly could explain why females are less susceptible to oxidative 
stress. 
 
 
5.5 Effects of testosterone treatment on hepatic functions in 
male ZDF rats  
 
Whether hypogonadal men, with or without T2D, should be treated with 
testosterone is a question of great concern. There are reports on positive 
effects on adiposity, insulin sensitivity and total cholesterol [255]. However, 
since androgen administration lowers antiatherogenic HDL-cholesterol, 
testosterone treatment might enhance cardiovascular disease risk [256]. In 
paper IV, we used treated the male obese ZDF rat with testosterone and 
compared the effects on the liver to the lean control ZDF rat. 
 
Insulin and glucose levels 
As expected, the blood glucose levels were higher in the obese ZDF rats 
compared to the lean controls. However, the testosterone treatment increased 
the glucose levels even further. Thus, the glucose tolerance was reduced in 
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these animals, indicating reduced uptake by peripheral tissues or enhanced 
hepatic glucose output. By calculating a HOMA-IR index we could hint that 
the over-all body insulin sensitivity was not significantly altered by the 
testosterone treatment. However, further measurements of the hepatic insulin 
sensitivity should be conducted before concluding the worsening effects of 
testosterone in the liver.  
 
Hepatic lipid content and serum lipid profiles 
After the observed reduction in glucose homeostasis, an increase in hepatic 
lipid content would be expected. However, the diabetic male ZDF rats 
showed reduced hepatic fat content and increased circulating levels of VLDL-
TG particles after testosterone treatment. Normalized hepatic lipid content 
could be beneficial for the diabetic state in the ZDF rats. But unless energy 
expenditure would be elevated to the same extent as the availability of fuel 
molecules in blood, maintained testosterone treatment over time would 
probably worsen the metabolic state in these rats.  
 
Hepatic gene expression 
To find an explanation for the ZDF-specific effects of testosterone, hepatic 
transcript profiles were generated and compared between lean and obese 
rats. In line with the results described above, most hepatic effects on gene 
expression were different between the groups. In the testosterone treated 
lean ZDF rats, a beneficial effect was observed on the expression of IRS2 
and Angptl4, indicating improved insulin sensitivity thus, improved 
regulation of glucose and VLDL output. Angptl4 expression is induced in 
adipose tissue and liver during fasting, and acts as a powerful signal to 
prevent fat storage, stimulate fat mobilization [257, 258] and hepatic insulin 
sensitivity [259]. Serum levels of Angptl4 in human subjects have been 
shown to inversely correlate with plasma glucose concentrations and 
HOMA-IR [259]. Further studies involving measurements of circulating 
levels of Angptl4 protein in hypogonadal men before and after testosterone 
replacement would help to evaluate the importance of our finding in a 
human perspective. 
 
In the obese ZDF rats, testosterone treatment had a great effect on de novo 
lipid synthesis, through inhibition of CHREBP and SREBP1c, and their 
target genes. This might partly be a consequence of higher SHP mRNA 
levels in the obese state, since SHP has been shown to down-regulate 
expression of CHREBP and SREBP1c. Lower rates of lipid synthesis 
together with enhanced capacity for FA oxidation (CPT1 and FGF21) and 
bile acid synthesis (CYP7A1) might explain the lowering effect on hepatic 
lipids observed in ZDF rats upon testosterone treatment. In addition, the 
transcription factor IRE-BP1 (insulin-response element binding protein-1), 
was significantly reduced by testosterone in the obese rats. If lower IRE-
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BP1 mRNA levels would also lead to lower IRE-BP1 protein and capacity 
to respond to insulin, hepatic IR might develop [260, 261]. 
 
Hepatic STAT3 activity 
Leptin treatment has been shown to improve IR in various animal models 
and to correct hyperglycemia and hyperinsulinemia in leptin-deficient 
animals and humans [262]. Hepatic leptin receptor signaling involves the 
activation of the transcription factor STAT3 by phosphorylation [263]. 
Hepatic STAT3 signaling has been shown to be essential for normal glucose 
homeostasis [264]. The degree of hepatic STAT3-phosphorylation was 
different between the groups of rats used in this study. To our surprise, 
testosterone seemed to reduce STAT3 activity in both lean and obese rats. 
This effect of testosterone was confirmed in vitro, using leptin-treated 
primary cultures of human hepatocytes. This suggests that testosterone has the 
ability to block hepatic actions of STAT3, a key mediator of leptin, essential for 
hepatic insulin sensitivity and normal glucose homeostasis. Consequently, 
liver-specific STAT3 KO mice have impaired glucose tolerance [264]. Here we 
demonstrate that testosterone is a potent inhibitor of hepatic STAT3-
phosphorylation. It is interesting to note that administration of estrogen to 
ob/ob mice improves the diabetic state and that hepatic STAT3 levels are 
increased [81]. These findings suggest that androgens and estrogens are having 
counter-acting effects on liver metabolism and that leptin receptor signaling 
may be a converging pathway involved in this. Finally, since testosterone 
treatment aggravates the diabetic state in ZDF male rats, it is suggested that the 
leptin status should be considered in situations of androgen treatment. 
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6 CONCLUSIONS AND FUTURE 
PERSPECTIVES 
 
The general goal of this thesis was to investigate if there is a relationship 
between sex differences in hepatic fuel metabolism and development of 
insulin resistance. This was mainly studied at the levels of hepatic gene 
expression, since hormonal regulation of gene expression plays an important 
role in maintaining metabolic homeostasis, and sets the basis for sex 
differences in important biological functions. By using whole-genome 
microarrays, we were able to identify hepatic metabolic pathways that are 
sex-dependent, affected by high-fat feeding and/or related to diabetes 
development. One important question remaining to address is whether males 
and females are differently affected by high-fat feeding-induced hepatic 
insulin resistance. We have preliminary data showing that short-term high-fat 
(safflower oil-enriched diet) feeding does not reduce hepatic insulin 
sensitivity, as compared to males that do develop insulin resistance. This 
should be extended to other measurements of insulin sensitivity and lipid 
metabolism, as well as more long-term feeding protocols. 
 
The studies in this thesis are of observational nature, but cause-effect 
relationships should be addressed in future studies to enable more definitive 
answers regarding molecular mechanisms involved in different situations of 
metabolic stress. However, by using all transcript profiles generated in this 
thesis it should be possible to find co-regulated genes of importance for sex-
different development of diet-induced T2D. This would also enable 
identification of cis- and trans-acting factors of importance for this. The use 
of in silico promoter analysis of co-regulated genes have previously been used 
in the prediction of transcription factor binding sites in the genomic sequences 
[103].  
 
In order to elucidate molecular sex basis for sex differences in transcription,  
Waxman et al recently used genome-wide in vivo mapping of transcriptional 
regulatory elements. By the use of a DNase hypersensitive method coupled to 
high-throughput sequencing, they were able to reveal sex differences in 1284 
hypersensitive sites of mice livers [265]. Also, continuous GH infusion 
suppressed the majority of male-specific sites and induced a set of female-
specific sites of these male livers, emphasizing the importance of extensive 
mapping of sex-different responses within the liver. 
 
While findings in gene expression only reflect the genotype of a system in a 
transcriptional network, knowledge about alterations in proteins and 
metabolites reveal the actual phenotype. To understand the complete system 
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of a cell, it is essential to link expression of transcripts and proteins with 
cellular metabolites. Hence, a strength of this thesis is reflected by our ability 
to compare transcript profiles with metabolite profiles (paper I and III), 
providing a unique opportunity to explore common and essential response 
mechanisms in the search for sex differences in hepatic metabolism and 
insulin sensitivity. As an example, we observed sex differences in the 
expression of key enzymes for gluconeogenesis, indicating an increase of 
HGO in the male rats. By performing in situ liver perfusion, we could show 
that the males did have higher levels of glucose output, confirming the 
expression data. Further, by using 1NMR spectroscopy other interesting 
findings was confirmed at the metabolic level. These results have to our 
knowledge not been observed before. This approach would be of interest to 
use for further investigations of sex differences in e.g. the response to high-fat 
diet. 
 
It would have been of interest to have a more translational approach in the 
study designs, to link the observations in the animal models with the human 
situation. However, studies in human liver are limited since liver biopsies 
cannot be routinely taken. Also, the treatments and their effects on the liver 
that we set out to investigate demanded a closed and supervised system as 
an animal model provides. Thus, as a next step, it would be of interest to use 
primary hepatocytes from humans to investigate the effects of the hormones 
included in this thesis. The results could then be compared to the animal 
studies. Hopefully, this approach will provide more evidence for the sex-
different hepatic metabolism and its relation to hepatic IR.  
 
Taken together, these findings suggest that the hepatic functions of female 
rats might contribute to a lower risk of developing lipid-induced oxidative 
stress, and hepatic IR. Observations of key metabolic transcripts suggest that 
the capacity of females to retain lipogenesis and the secretion of VLDL-TG 
might be related to this. We speculate that this together with higher rates of 
FA oxidation and glucose production in males, might at least partly explain 
why males are more prone to develop insulin resistance, T2D and the 
metabolic syndrome.  
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